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A B S T R A C T
The simultaneous intake of food and drugs can have a strong impact on drug release, absorption, distribution, meta-
bolism and/or elimination and consequently, on the efficacy and safety of pharmacotherapy. As such, food-drug
interactions are one of the main challenges in oral drug administration. Whereas pharmacokinetic (PK) food-drug
interactions can have a variety of causes, pharmacodynamic (PD) food-drug interactions occur due to specific phar-
macological interactions between a drug and particular drinks or food. In recent years, extensive efforts were made to
elucidate the mechanisms that drive pharmacokinetic food-drug interactions. Their occurrence depends mainly on the
properties of the drug substance, the formulation and a multitude of physiological factors. Every intake of food or drink
changes the physiological conditions in the human gastrointestinal tract. Therefore, a precise understanding of how
different foods and drinks affect the processes of drug absorption, distribution, metabolism and/or elimination as well
as formulation performance is important in order to be able to predict and avoid such interactions. Furthermore, it must
be considered that beverages such as milk, grapefruit juice and alcohol can also lead to specific food-drug interactions.
In this regard, the growing use of food supplements and functional food requires urgent attention in oral pharma-
cotherapy. Recently, a new consortium in Understanding Gastrointestinal Absorption-related Processes (UNGAP) was
established through COST, a funding organisation of the European Union supporting translational research across
Europe. In this review of the UNGAP Working group “Food-Drug Interface”, the different mechanisms that can lead to
pharmacokinetic food-drug interactions are discussed and summarised from different expert perspectives.
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1. Introduction
Food-drug interactions are a major threat to safe and effective oral
pharmacotherapy. Understanding the underlying mechanisms is es-
sential in avoiding these to the best extent (O'Shea et al., 2018).
Therefore, various research groups have studied a variety of mechan-
isms potentially leading to food-drug interactions. Based on these in-
vestigations, a distinction between pharmacokinetic (PK) and/or
pharmacodynamics (PD) food-drug interactions can be made (Fleisher
et al., 1999; Schmidt and Dalhoff, 2002). Pharmacodynamic food-drug
interactions are caused by a specific interaction between a drug and a
component of the food that results in a particular pharmacological ef-
fect. A prominent example of this type of food-drug interaction is the
“cheese reaction” which is caused by the mediation between tyramine,
a constituent of cheese or raw sausages, and inhibitors of the enzyme
monoaminoxidase such as tranylcypromine (Brown et al., 1989). In this
case, the mechanism of the food-drug interaction is well defined and
thus, can be easily avoided by excluding particular foods from the daily
diet or if possible, by changing the formulation of the drug product.
However, owing to the growing number of nutrients and dietary sup-
plements, pharmacodynamic interactions may remain undetected
(Gurley et al., 2012; Gurley, 2012; Tsai et al., 2012). It should also be
noted that this type of pharmacological food-drug interaction is not
limited to orally administered drugs.
The intake of food and/or drinks other than water can also affect the
pharmacokinetic profile for different specific or unspecific reasons. The
most prominent example of a specific pharmacokinetic food-drug effect
is the interaction between grapefruit juice and drugs like cyclosporine
and felodipine (Dahan and Altman, 2004). The interaction can result
through different mechanisms, including the inhibition of CYP3A4
metabolism as well as inhibition of uptake and efflux membrane
transporters. This type of food-drug interaction can easily be avoided by
omitting certain foods or drinks. On the other hand, for unspecific
pharmacokinetic food-drug interactions, the situation is complicated
from the onset of functional changes in the gastrointestinal tract in-
duced by the intake of food and/or drink. These include altered gastric
emptying kinetics, increased luminal bile salt concentrations or in-
creased hepatic perfusion (Fleisher et al., 1999; O'Shea et al., 2018;
Schmidt and Dalhoff, 2002).
This review has been established as part of the European COST in-
itiative UNGAP (“Understanding Gastrointestinal Absorption-related
Processes”) working group “Food-Drug Interface” with the aim to
comprehensively discuss pharmacokinetic food-drug interactions
(Fig. 1). This includes an explanation of how the intake of drinks and
food can change the physiology of the human GI tract and how this may
affect the pharmacokinetic profile of orally administered drugs; a de-
scription of specific effects of particularly relevant liquids such as milk,
grapefruit juice and alcoholic beverages; and the role of the formula-
tion.
2. Regulatory considerations of food-drug interactions
2.1. Testing for pharmacokinetic food-drug interactions
Due to the relevance and the risk associated with certain food-drug
interactions, the evaluation of the effect of food or drink on the phar-
macokinetic profile of a drug is an integral part of the registration
process for a new drug product, i.e. a drug that is registered for the first
time in a specific region for human use and therefore excluding gen-
erics. Typically, the food effect on the oral bioavailability of the drug is
determined in a clinical study conducted with healthy volunteers and in
which plasma concentration-time profiles after fasted and fed admin-
istration of the test drug are compared on the basis of pharmacokinetic
parameters. Analogous to the evaluation of bioequivalence, the pre-
sence of a food effect is assessed primarily in terms of changes in the
area under the plasma-concentration-time curve (AUC), the maximum
concentration in the plasma (Cmax) and in some cases, the time at which
this concentration is observed (tmax). The subsequent recommendation
provided in the product label is dependent on the difference in exposure
with or without food, as well as the relationship between concentration
and effect of the drug.
Since the extent of a food effect on oral bioavailability strongly
depends on the type and composition of the food as well as on the
dietary protocol during the study, the United States Food and Drug
Administration (FDA) issued a guidance in 2002 for conducting bioa-
vailability and bioequivalence studies under fed conditions (FDA,
2002). In this way, an increased level of standardisation has been
achieved in clinical trials, enabling a better understanding of the ob-
served effects. In recent years, the European Medicines Agency (EMA)
has largely adapted its corresponding guidelines to the recommenda-
tions of the FDA. The current FDA and EMA guidelines require the
administration of a high-caloric (800–1000 kcal) and high-fat
(500–600 kcal of total calories derived from fat) test meal for the in-
vestigation of food effects on oral drug bioavailability (EMA, 2012;
FDA, 2002). This meal is intended to trigger a maximum physiological
response and thus, represents a worst-case scenario. Both FDA and EMA
guidelines further contain a concrete example for the composition of
such a test meal; two slices of toast with butter, two slices of fried
bacon, two eggs fried in butter, 113 g hash-brown potatoes as well as
240mL of whole milk (EMA, 2012; FDA, 2002). This so-called FDA
standard meal meanwhile represents the general standard for food ef-
fect studies and therefore, the majority of pharmacokinetic data on food
effects that were published in the last 15 years are based on this par-
ticular meal. In the EU regulatory setting, in case the drug will be re-
commended to be taken with a meal, studies of the effects of a ‘mod-
erate’ meal are endorsed and on occasions, different food compositions
(such as a carbohydrate-rich meal or snacks) may be conducted as well
(EMA, 2012).
As indicated in the guidelines, the drug product to be tested is ad-
ministered 30min after the beginning of meal consumption with
240mL water. The final evaluation of the food effect is based on the
90% confidence intervals of the ratios of AUC and Cmax obtained fol-
lowing drug administration under fasted and fed conditions. Based on
the relationship between concentration and effect of the drug, an
Fig. 1. Overview of specific and unspecific pharmacokinetic food-drug inter-
actions covered in this review.
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acceptance range is defined. The acceptance range may, as in bioe-
quivalence assessments, be 80–125% but can be broader or smaller
dependent on the therapeutic window of the drug. If the confidence
intervals determined after drug administration in fed state are outside
the predefined acceptance range, a clinically relevant food effect is
considered to be present. According to the ratio of the AUC determined
after fasting and after fed drug administration (Fig. 2), positive (in-
creased oral bioavailability) and negative (reduced oral bioavailability)
food effects are distinguished (FDA, 2002).
2.2. Impact of food-drug interactions on dosing instructions
The fact that food can affect the pharmacokinetics of drugs such as
cyclosporine, nifedipine or theophylline has been known for> 30 years
(Challenor et al., 1987; Karim et al., 1985; Mueller et al., 1994).
Nonetheless, the topic of food-drug interactions remains highly relevant
since many newly discovered drugs show poor aqueous solubility, but
sufficient permeability (Williams et al., 2013). Consequently, their
bioavailability often depends on the luminal gastrointestinal (GI) con-
ditions and thus, drugs can sensitively react to food-induced changes of
the luminal conditions in the human GI tract. Kang and Ratain stated in
a recent publication that significant food-drug interactions are present
for 34 of the 99 orally administered drugs approved by the FDA be-
tween January 2000 and May 2009 (Kang and Ratain, 2010). In par-
ticular, novel oral anticancer drugs often show relevant changes in oral
bioavailability after administration together with food, because many
of them have a poor aqueous solubility and are typically administered
in relatively high doses (Willemsen et al., 2016).
The influence of food on the pharmacokinetic profile of the tyrosine
kinase inhibitor lapatinib is a particularly striking example in this re-
gard. Compared to its administration in fasted state, the oral bioavail-
ability of a single dose of 1500mg lapatinib increases on average by
325% (4.25 fold) after administration with a high-caloric standard meal
(Koch et al., 2009). Thus, the oral exposure of one tablet administered
with food is comparable to more than four tablets administered in
fasted state. Nonetheless, it is recommended to take lapatinib either 1 h
before or 1 h after eating, rather than taking a smaller dose with the
meal itself. This intake advice was the topic of an intense debate that
started already in 2007 and that was initiated by the American oncol-
ogists Mark Ratain and Ezra Cohen (Ratain and Cohen, 2007). They
suggested to reconsider this intake advice, arguing that the food-in-
duced increase in oral bioavailability would enable smaller doses and
thus, reduce the cost of treatment with this highly expensive drug. They
stated that in the US $1700 per month per patient can be saved by
dosing the drug with food. In addition, they argued that the severe GI
side effects of this drug, which are triggered primarily by the non-ab-
sorbed portion of the drug, could possibly be reduced. Thus, extensive
discussions in patient access to and reimbursement of expensive drugs
may benefit from user instructions offering two different approaches to
the recommended dose and associated user instruction. For the anti-
tumor drug vemurafenib, for which AUC increases approximately 5-fold
when given with food, in the EU product information (i.e., the Summary
of Product Characteristics and Package Leaflet; (SmPC/PL)) the advice
is given that it “may be taken with or without food, but consistent in-
take of both daily doses on an empty stomach should be avoided”,
however, no lower dose in the presence of food is actually advised. To
the best of our knowledge, there is not yet any authorised dosing in-
structions that uses a food-drug interaction to lower the dose as com-
pared to the situation without food. An extensive risk evaluation of such
approach would be warranted first. Aspects to be considered would, for
example, need to include the risk of swapping doses and instructions by
a variety of patients and in a variety of settings, the ability of patients to
consistently take (high-caloric) meals, the risk for weight gain/obesity,
or the risk of incidentally taking the drug without food.
In real world settings, patients commonly take oral products with
food or drink. From a regulatory perspective, this can only be accepted
when the instruction to take the drug with food or a drink other than
water is recommended in the SmPC. However, health care professionals
and patients commonly consider that this regulatory approach is un-
realistic given that such recommendations are failing for many mar-
keted products just because of the lack of data rather than a real in-
teraction. Thus, health care professionals urgently require deeper
knowledge regarding the underlying mechanisms of food-drug inter-
actions to understand which recommendations and/or warnings require
urgent attention in real-life settings. At the same time, both patients and
health care professionals would benefit if industry would update the
product information from “old” products by clearly indicating if a food-
drug interaction may occur or not, meaning that regulators would need
to accept statements like “A food-drug interaction has not been ob-
served with a high caloric meal etc.”
3. Food-induced changes of human GI physiology and their
relevance for oral drug delivery
Food intake leads to various changes of the physiological conditions
in the human gastrointestinal (GI) tract, which can affect the pharma-
cokinetic profile of a drug by changing its release, absorption, dis-
tribution, metabolism and/or elimination. These food-drug interactions
are unspecific, which means that they will apply to any formulation
that is orally ingested. However, their relevance depends on the prop-
erties of the drug and the formulation. For instance, if solubility is
limiting oral drug absorption, the availability and composition of lu-
minal fluids will be of major importance. In the following chapters, we
describe how food changes the luminal conditions in the human GI tract
and how this can affect drug absorption.
3.1. Fluid volumes and their kinetics in stomach and intestine
The availability of luminal fluids in the gastrointestinal tract is a
prerequisite for drug release and absorption of orally administered
drugs. In addition, the volume of fluid available for drug dissolution
may determine the luminal concentration and in the case of drugs with
Fig. 2. Pharmacokinetic classification of food-drug interactions (food effects).
Adapted from Koziolek et al., 2016.
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poor aqueous solubility, the amount of drug that can be dissolved in
certain parts in the human GI tract. Therefore, it is important to know
the volumes of fluids present in the stomach and the small intestine.
The presence of a concentration gradient between the intestinal lumen
and the blood is the driving force for passive drug uptake (Grimm et al.,
2018b; Koziolek et al., 2016; Van Den Abeele et al., 2017b). Ad-
ditionally, various transporters and drug-metabolising enzymes in the
enterocytes may be saturable and therefore, small changes in the lu-
minal concentration can have dramatic effects due to non-linear phar-
macokinetics in case of drugs with poor aqueous solubility. Besides
various effects on luminal drug concentrations, the volume of the gas-
tric content exerts important effects on formulation transit, particularly
on gastric residence time. This aspect will be considered in more detail
in other parts of the review.
For bioequivalence and bioavailability studies, an overnight fasting
period of at least 8 h (EMA) or 10 h (FDA) is requested in the regulatory
guidelines (EMA, 2010; FDA, 2002). Recent Magnetic resonance ima-
ging (MRI) studies in healthy volunteers have shown that after such an
overnight fast, fluid volumes of about 10–50mL are typically present in
the stomach (Table 1). A pronounced intra-individual variability of
these values has been reported and needs to be taken into consideration
as the remaining fluid partially defines the physicochemical starting
conditions after intake of an oral formulation.
Nonetheless, these low residual fluid volumes after a long overnight
fast do not represent the initially available fluid volume after for-
mulation intake. In clinical trials, an oral formulation is typically ad-
ministered with a defined volume of water, i.e. at least 150mL ac-
cording to EMA guidelines (EMA, 2010) and 240mL according to FDA
guidance (FDA, 2002). The fluid volumes initially available after the
intake of 240mL water are summarised in Table 1. Due to technical
reasons, these values were typically collected around 2min after water
intake. The administered volume of water is typically emptied rapidly
within 15–45min most often following a first-order kinetic (Fig. 3)
(Grimm et al., 2017; Mudie et al., 2014).
Since fluid volumes have a multitude of effects on luminal drug
concentration, it is also expected to significantly contribute to the oc-
currence of food effects on oral drug bioavailability. As aforemen-
tioned, for bioavailability and bioequivalence studies conducted under
fed conditions, the high-fat and high-caloric FDA standard meal is ty-
pically applied (EMA, 2010; FDA, 2002). The standardisation of meal
composition is essential since caloric density and specific effects of
macronutrients are known to affect the gastric content volume (Goetze
et al., 2007; Grimm et al., 2017). MRI investigations have shown that
initially after intake of the FDA standard meal, the postprandial gastric
content volume amounts to 580 ± 38mL (n= 12) (Koziolek et al.,
2014b). These strongly elevated gastric volumes are present for several
hours (Fig. 3) since caloric chyme is typically emptied with a rate of
2–4 kcal/min (Koziolek et al., 2013). This results in an apparent gastric
emptying rate of 1.7 ± 0.3mL/min. Thus, even 6 h after intake of the
standard high-caloric and high-fat meal subjects cannot be assumed to
be fasted. This is also supported by transit data of telemetric capsules
(Koziolek et al., 2015b). Thus, the common intake advice to take a drug
2 h after meal will not result in a fasted state administration of the drug,
if a larger meal was consumed. Thus, food effects on oral bioavailability
may still occur. Also after a moderate meal (approximately
400–500 kcal with fat contributing to around 150 kcal) as advised in the
EU guidelines (EMA, 2012), fasting conditions are unlikely to be pre-
sent 2 h after the intake of such a meal (Armand et al., 2004).
Data for gastric volumes after different meals were reported to be
even higher than 1000mL. Thus, although the FDA standard breakfast
is regarded as a worst-case scenario, higher fluid volumes can occur in
real life (Koziolek et al., 2013). However, for drug dissolution, the
volume of free fluid is of major importance and this will be significantly
lower than the volume of the gastric contents in total. It should be noted
that the FDA standard meal consists partially of solids. Most likely, a
large portion of the watery fluids will be absorbed by food components
such as toast. In addition, the FDA standard meal consists of larger
amounts of lipids. Recent MRI studies have reported values of ap-
proximately 9.5% (v/v) fat for the gastric content after ingestion of the
FDA standard meal (Koziolek et al., 2014b). Thus, it remains unclear
how much free fluid is really available for disintegration and/or dis-
solution processes. Due to secretory activity, free watery fluid will be
mainly present near the stomach wall (Marciani et al., 2001). This as-
pect is highly relevant for luminal drug distribution. If a formulation is
deposited in the fundus or corpus, a homogeneous distribution of the
drug throughout the whole stomach will be unlikely owing to the highly
viscous and heterogeneous nature of the gastric content after the intake
of solid meals (Koziolek et al., 2014a). Several groups have shown that
the gastric content is highly heterogeneous after intake of a solid meal,
with sedimentation and pronounced layering of solids, fats and fluids.
Both, the gastric secretions and the fat components were observed to
lay on top of the chyme depending on the meal composition and on the
time of evaluation (Goetze et al., 2006; Koziolek et al., 2014b; Sauter
et al., 2012; Steingoetter et al., 2015). Thus, the homogenisation of
meal components which is often done for in vitro simulations produces
an artificial situation with respect to the amount and the physico-
chemical properties of the luminal contents. A more detailed explana-
tion of the physicochemical conditions in stomach and small intestine
can be found in the following paragraphs.
In addition to the gastric content volume after meal intake, one also
needs to consider the volume as well as the fate of the fluid co-ad-
ministered during drug intake. As aforementioned, a formulation is
typically ingested with 150 or 240mL of water in clinical trials.
Assuming perfect mixing of chyme with the co-administered water,
water intake would result in a gastric content volume of 679 ± 80mL
(Koziolek et al., 2014b). However, recent data have shown that this
seems to be incorrect for most solid meals (Grimm et al., 2017). It has
been shown in recent MRI studies that the water does not mix very well
with the highly viscous and fatty chyme of the standard meal. As a
consequence, it is rapidly emptied from the stomach along the stomach
wall. This physiological phenomenon is called Magenstrasse, from the
German meaning stomach road. Therefore, higher amounts of freely
available fluid may only be present shortly after formulation intake and
typically only in regions near to the stomach wall (Grimm et al., 2017;
Koziolek et al., 2014b, 2016; Pal et al., 2007). This phenomenon can
have certain consequences for oral drug delivery as the water flow can
Table 1
Gastric and small intestinal fluid volume determined at different conditions.
Gastric fluid volume Small intestinal fluid volume
Mean ± SD Ref. Mean ± SD Ref.
10 h overnight fast 35 ± 7mL
(n=12)
25 ± 18mL
(n=120)
a
b
43 ± 14mL (n= 12)
51 ± 33mL (n= 24)
105 ± 72mL (n=12)
91 ± 68mL (n= 16)
a
d
f
g
240mL of water 242 ± 9mL
(n=12)
256 ± 36mL
(n=8)
292 ± 21mL
(n=8)
270 ± 20mL
(n=6)
a
b
b
c
Maximum of 92 ± 24mL
after 12min (n= 12)
Maximum of
107 ± 69mL after
15min (n= 6)
a
d
FDA breakfast 580 ± 38mL
(n=12)
e n/a
a Mudie et al., 2014.
b Grimm et al., 2018a.
c Grimm et al., 2017.
d Grimm et al., 2018b.
e Koziolek et al., 2014b.
f Schiller et al., 2005.
g Marciani et al., 2010.
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entrain a certain amount of drug from the stomach. Thus, a drug be-
comes available for absorption in the small intestine much faster than it
would be possible in case of the slower gastric emptying together with
chyme (Koziolek et al., 2016).
After the formulation itself, or a dispersion or solution of the drug
substance is emptied from the stomach, the small intestinal volumes
will represent the dissolution medium and determine the resulting
concentrations of the drug. Recent MRI studies have investigated small
intestinal fluid volumes after an overnight fast and after intake of fluids
and food.
As can be seen from Table 1, after intake of a formulation with
240mL of water, the available small intestinal fluid volume in the
fasted state is not as high as the administered fluid volume. In contrast,
it is rather comparable to or slightly higher than residual fluid volumes.
Fig. 4 illustrates the increase in small intestinal fluid volume within the
first minutes that is followed by a decrease to mean values between
70mL and 80mL from 30min after intake (Grimm et al., 2018b; Mudie
et al., 2014).
Moreover, it must be considered that the fluids present in the small
intestinal volume are not coherent and that the different regions in the
small intestine are not constantly wetted. In fact, the small intestinal
fluid volume is typically distributed in several fluid pockets along the
small intestines (Grimm et al., 2018b; Mudie et al., 2014; Schiller et al.,
2005). Before the administration of the formulation together with
water, there are approximately 8 ± 1 fluid pockets present that have a
mean volume of 4 ± 1mL each. Subsequently, the number of pockets
increases to about 15 ± 1 fluid pockets with a volume of approxi-
mately 7mL 12min after administration. Although the number of
pockets decreases afterwards, their mean volume remains elevated
(Mudie et al., 2014). Since most of the fluid pockets are rather small,
oral formulations are most of the time either only partially in contact
with fluids or without any contact to fluids during intestinal transit. For
example, Schiller et al. have reported that about 50% of the tested
monolithic formulations are not or only partially in contact with in-
testinal fluids after fasted intake (Schiller et al., 2005). Thus, the
available volume for dissolution processes might be overestimated in
common approaches, even if a physiological amount between 50 and
100mL is simulated.
It is generally believed that elevated small intestinal fluid volumes
in the fed state can contribute to the occurrence of food effects by in-
fluencing the luminal concentration as well as the intestinal surface
area available for drug absorption (Grimm et al., 2018b). Although this
theory seems obvious, it is not clear whether small intestinal fluid
volumes are really elevated after food intake. Schiller et al. reported a
decreased small intestinal fluid volume 1 h after the intake of a stan-
dardised meal (Schiller et al., 2005). However, the determination of
fluid volumes in the small intestine can be strongly affected by the
imaging procedure. In the heavily T2-weighted MRI acquisitions that
are commonly used for this purpose, only freely mobile water provides
a high signal intensity (Hoad et al., 2007). However, the small intestine
is mainly filled with chyme, which has a lower signal intensity.
Therefore, luminal contents with a signal intensity below the quantifi-
cation threshold of these MRI sequences are not fully captured. That
leads to a possible underestimation of the total fluid volume present in
the small intestine. Nonetheless, although the water content of the
chyme is less mobile, bound or trapped in the food matrix, it might still
be available for dissolution processes. This needs to be kept in mind
when interpreting these data as considered in a recent article which
called the evaluated volume “apparent small intestinal water content”
(Marciani et al., 2013). Furthermore, it needs to be considered that the
apparent fluid volume is dynamically distributed throughout the whole
small intestinal lumen and that absorption and secretion of water are
highly dynamic processes. This leads to a specific net flux of water
across the intestinal wall. Thus, free fluids present in the small in-
testinal lumen do not necessarily arise from the ingestion of fluid, but
can also result from intestinal secretion. The direct effect of this flux on
drug absorption in humans seems to be negligible (Artursson et al.,
1999; Lennernäs et al., 1994), although the flux itself and therefore the
intestinal fluid volume indeed depends on several components present
with food (e.g. sodium or carbohydrates) (Erokhova et al., 2016; Grimm
et al., 2018b).
Due to the complex shape and inhomogeneous signal arising from
mixed/solid meals such as the FDA standard meal with most imaging
techniques, no data is currently available on the corresponding post-
prandial small intestinal fluid volumes for the FDA standard breakfast
and only very few data available for other meals. For a (semi-)solid
meal of rice pudding with bran, postprandial changes in small intestinal
water content are characterised by an instantaneous decrease of volume
followed by a slow increase of small intestinal filling (Marciani et al.,
2010). An increase in small intestinal water content was also reported
for meals consisting of lettuce or rhubarb (Wilkinson-Smith et al.,
2018). On the other side, specific food components can also decrease
the freely available water as was shown for whole meal bread (Marciani
et al., 2013). The effect of different caloric liquids on small intestinal
media volume has been studied by various research groups. Interest-
ingly, the presence of glucose typically reduces the amount of available
fluids (Grimm et al., 2018b; Marciani et al., 2010; Murray et al., 2014),
Fig. 3. Mean gastric content volume (GCV) ± SD determined in 12 healthy
volunteers immediately before and after up to 360min after intake of 240mL of
water in clinically relevant fasted state and fed state scenarios.
Adapted from Koziolek et al., 2014b and Mudie et al., 2014.
Fig. 4. Small intestinal fluid volumes (mean ± SD) after intake of 240mL
water in fasted state.
Adapted from Mudie et al., 2014 (n=12) and Grimm et al., 2018b (n= 6).
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whereas fat has been shown to increase substantially the amount of
fluid in the small intestine (Hussein et al., 2015). Further studies have
demonstrated that grapefruit juice or beverages containing fructose can
increase the small intestinal fluid volume in a considerable manner.
Thus, the effect of grapefruit juice on the pharmacokinetic profile of an
orally administered drug is not necessarily caused by specific interac-
tions with uptake and efflux transporters or metabolising enzymes but
can also be caused by changed luminal conditions.
After small intestinal transit, the colonic volumes can also be re-
levant if meaningful drug absorption can occur in the colon or if colon-
targeted formulations are applied. Generally, colonic transit is much
longer and hence, it is more difficult to dissect whether food effects
result from co-administration of food with the drug product, or from
food intake that happened hours before intake of a formulation. With
regard to transit times of food components and chyme as well as of
formulations, a drug product inside the colon might face a milieu de-
termined also by meals that were ingested long before the intake of the
drug product itself (Camilleri et al., 1989; Chaddock et al., 2014;
Schneider et al., 2016). It must be considered that the idea of a ‘fasting
colon’ is highly artificial and can only be achieved by the use of laxa-
tives. In contrast, during clinical studies the dietary protocol is highly
standardised and therefore, an orally administered formulation that
enters the colon either intact or in form of dispersed API, will mostly
face a ‘non-fasted colon’. A standardisation of the subjects' feeding re-
gimen should ideally start days before a drug is administered in a
clinical study.
The volume of colonic contents can be up to 1 L (Sandberg et al.,
2015), but these high volumes consist mainly of food residues and
human and bacterial cells as well as cell debris. Due to high viscosity
and the limited amount of free fluid, this volume is typically not
available for dissolution processes. With respect to free watery fluid,
which is of higher relevance for oral drug delivery, it can be noted that
the volumes are typically low and that the fluids are distributed in ir-
regular fluid pockets. These are mainly present in the proximal part of
the colon. A very variable amount of free fluid volume of 13 ± 12mL
(n=12) with a range of 1–44mL inside these pockets was reported for
entire colon (Schiller et al., 2005). Another MRI study observed com-
parable values of 0–49mL available free fluid distributed over 11 ± 5
pockets fluid pockets in the whole colon (Murray et al., 2017). Al-
though there can be long-term effect of several food components on
colonic filling, due to spatial separation rapid and direct effects of food
intake on a formulation already residing in the colon are less likely.
In conclusion, the altered volume of luminal fluids, especially in
stomach and small intestine, as well as their kinetics are likely to play a
major role in the occurrence of food effects. In particular, even isolated
changes in available fluid and gastric emptying are considered to be
factors which may lead to changed tmax, Cmax or multiple peaks without
necessarily altering bioavailability.
3.2. Gastric and intestinal motility, gastric emptying and intestinal transit
The intake of food leads to an increase in the motility that is dif-
ferent in each part of the gastrointestinal tract and this motor response
is expected to affect the dissolution and absorption of the drug.
Anatomically, the stomach is divided into a fundus, corpus and
antrum region, but when it comes to motor function, two parts can be
distinguished: the proximal stomach, consisting of the fundus and the
proximal part of the corpus, and the distal stomach consisting of the
distal part of the corpus and the antrum. The motility of the proximal
stomach is characterised by a maintained status of contraction of the
smooth muscle (tone), whereas the distal stomach generates phasic
contractions. During the interdigestive phase, the proximal stomach
muscle tone is high. The distal stomach however is engaged in a re-
current motor pattern known as the migrating motor complex (MMC)
(Janssen, 2011). This complex involves the stomach and the majority of
the small intestine (but not the distal small intestine) with three phases:
phase I, a quiescent phase with no contractions; phase II with until
recently considered random contractions; phase III with a sudden onset
of repetitive contractions that also ends abruptly. Phase III can start in
the stomach or in the proximal small intestine and migrate toward the
distal ileum. Antral phase III activity is defined as the occurrence of
regular contractions for at least 2min at a frequency of 2–3 contractions
per min simultaneous with, or preceding, phase III activity in the
proximal duodenum. In the duodenum, phase III contractions have a
frequency of 11–12 contractions per min and last for at least 3min. The
duration of the cycle is approximately 130min and feeding interrupts
the complex. The contribution of each phase to the cycle length in the
antrum is 55% for phase I, 41% for phase II and 4% for phase III. Gastric
pH fluctuates during the MMC, with the antral pH being lowest (more
acidic) just prior to the start of phase III contractions, and higher at the
start of phase I. This change in pH is due to an increase in acid and
pepsin secretion that accompanies phase III of the MMC, and bile-free,
bicarbonate reflux from the duodenum. Intestinal and pancreatic se-
cretion of water, bicarbonate and pancreatic enzymes increase during
phase III contractions of the small intestine. The integrated secretory
activity that occurs in parallel with the motility phases has been re-
ferred to as the secretory component of the MMC (Deloose et al., 2012).
As soon as food is ingested, stomach motility changes. The proximal
stomach relaxes to accommodate the incoming food, then a tonic con-
traction of the proximal stomach pushes the food distally, whereas the
distal stomach mixes and grinds the food by powerful and regular
contractions. The duodenum is exposed to nutrients early after the in-
gestion of food, which activates a multitude of duodeno-gastric nega-
tive-feedback mechanisms, mediated through vago-vagal reflexes and
hormonal signals (GLP-1, PYY, and CCK, among others). The role of this
feedback is to delay the arrival of acidic, hyperosmotic, or calorie-rich
gastric contents into the duodenum by inhibiting proximal gastric tone,
gastric phasic contractions, and by stimulating closure of the pylorus
(Farré and Tack, 2013).
It has been demonstrated that the physical consistency, fat content
and caloric load of the meal play a relevant role in regulating the motor
response of the stomach. In general, liquids of low caloric density empty
under the pressure gradient created by the fundus tone and the little
motor action of the distal stomach in exponential fashion. Higher ca-
loric liquids or homogenised solids empty almost linearly under the
pressure gradient from the fundus and coordinated antropylor-
oduodenal motility. Digestible food of more solid consistency requires
antral trituration until the particle size is reduced (Pasricha et al.,
2017). Historical data indicated that the particle size needs to be in the
order of 2mm, but more recent studies with indigestible markers
showed that gastric emptying of 4.2 mm diameter cubes was similar to
the emptying of smaller markers (Stotzer and Abrahamsson, 2000).
Food reduced to small particles empties linearly from the stomach at a
rate similar to that of a homogenised solid meal. Trituration involves
establishing liquid shearing forces where solids and liquids are re-
peatedly pushed against a closed pylorus. The time that the stomach
takes to reduce the particles may explain the lag phase observed before
emptying can start. Thus, gastric emptying occurs in 2 periods: the lag
period and the post-lag, linear emptying period. Non-digestible solids
are usually emptied from the stomach with the inter-digestive MMC
(Pasricha et al., 2017). Depending on physical consistency, fat content
and caloric load of the meal, the gastric residence time of non-digestible
solids can be up to several hours (Weitschies et al., 2010). The same
applies to non-disintegrating formulations such as enteric-coated or
matrix tablets. These are not emptied by the fed motility pattern and
can only be emptied if the MMC returns. The gastric residence time of
non-disintegrating formulations generally depends on the prandial
status, the timing of dosing as well as the properties of the formulation.
Gastric emptying of non-disintegrating radio-labelled tablets was re-
ported to be quicker in the fasted (37min) when compared to fed state
(149min) (Fadda et al., 2009).
Gastric motility also plays a crucial role for the in vivo performance
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of modified release (MR) formulations. It is known that during gastric
transit high shear forces of up to 500mbar can arise and cause dose
dumping (Koziolek et al., 2018). This effect was nicely shown for var-
ious hydrogel matrix tablets by Garbacz et al. (2010, 2014). In a recent
Magnetic Marker Monitoring study, Jain et al. have demonstrated that
the rate of erosion of hydrogel matrix tablets is different after fasted and
fed administration of the formulation due to different motility patterns
(Jain et al., 2014). The continuous motility in the fed stomach caused a
faster erosion. The loss of modified release characteristics, after ad-
ministration of a non-disintegrating MR product in the fed state, has
been described in several studies as the most likely reason for the ob-
served changes in plasma levels compared with the fasted state (Davis
et al., 2009; Karim et al., 1985; Schug et al., 2002a, 2002b, 2002c).
In contrast, only few studies have investigated the possible role of
gut motor response in affecting drug dissolution and absorption of
immediate release (IR) products. Oral formulations that disintegrate in
the stomach will be emptied together with the gastric contents, but the
rate of gastric emptying depends on the distribution of the drug within
the stomach. This process is also affected by gastric motility. It is
generally assumed that mixing is poor in the proximal part, whereas it
is more effective in the distal part. Studies with magnetically labelled
extended release tablet have demonstrated that increased plasma peak
drug concentrations after intake of food were mainly caused by the poor
mixing in the proximal part of the stomach (Weitschies et al., 2005).
Thus, the initial deposition behavior of a formulation will affect the rate
of drug delivery to the small intestine (Koziolek et al., 2016).
More recent studies, in which high-resolution antro-duodenal
manometry was applied along with aspiration of contents and blood
sampling, have suggested that the phase of MMC seems to influence
both drug absorption and dissolution (Van Den Abeele et al., 2017a).
Evaluation of drug concentrations measured in different regions of the
stomach with the well-established technique of the intraluminal sam-
pling has shown a clear trend toward better mixing of an orally ad-
ministered drug with gastric contents when dosed in the presence of
gastric contractions. This results in a more homogeneous distribution of
the drug throughout the stomach compared to dosing in the absence of
gastric contractions (Van Den Abeele et al., 2017a). In addition, Hens
et al. have shown in another study that Cmax seems to be higher if the
time to phase III contraction is shorter (Hens et al., 2017).
In contrast, the small intestine postprandial motility is still poorly
understood. It has been indeed demonstrated that meals induce dif-
ferent contractions according to solubility and viscosity, but a clear
influence of nutrient composition has not been reported. Normal small
intestine transit takes up to 5 h (Farré and Tack, 2013). A recent study
has shown that the small intestinal transit time of non-disintegrating
radio-labelled tablets was similar in fasted and fed state (204 vs.
210min) (Fadda et al., 2009). This circumstance is not surprising since
the formulations were most likely emptied into a fasted small intestine
by the MMC. When the same tablets were ingested after a first meal but
45min before a second meal, two different patterns could be observed.
Some subjects had an accelerated small intestinal transit (100min),
whereas some other subjects showed a similar small intestinal time
transit to the fed state (185min). This difference was the result of dif-
ferent time points of gastric emptying. If the tablet was emptied before
the next meal, incoming food pushed the tablet through the small in-
testine, which resulted in faster transit. If the tablet was retained until
intake of the next meal, it could not be emptied by the fed motility
pattern and was emptied by the MMC after the stomach returned into
fasted state. Even if drug absorption was not evaluated in this study, the
authors speculated that for drugs with a narrow small intestinal ab-
sorption window and modified release (MR) systems, the timing of food
administration after dosing could be critical.
Recent findings applying high-resolution manometry have demon-
strated that colonic motility is mainly represented by non-propagating
(simultaneous) contractions and retrograde activity and both these
activities increased soon after the meal. These colonic motor patterns
have the role of retarding the arrival of colonic content to the rectum
and of favouring the retrograde filling of the transverse and ascending
colon where the propagating contractions normally start. Propagating
contractions, including the high-amplitude propagating contractions
associated with movements of solid colon content, represent a minority
of the colonic activity and are normally more frequent about 1–2 h after
the meal and upon awakening (Corsetti et al., 2018). The reason of this
is probably related to the fact that, in these moments of the day, the
arrival of the content accumulated in the distal small intestine during
the night and during the inter-digestive periods determine the disten-
sion of the ascending and transverse colon that trigger the propagating
activity. The prevalence of non-propagating activity explains the fact
that the normal colonic transit time is slower (about 35 h) when com-
pared with the small intestine. This allows the colon to perform its
functions of absorption, fermentation and reservoir organ. The colonic
motor response to food is slower in onset but more prolonged with a
fatty meal compared with a carbohydrate meal. Ingestion of lipids sti-
mulates mainly non-propulsive colonic motility. Non-absorbable car-
bohydrates inhibit colonic water absorption and stimulate colonic
transit.
3.3. Luminal pH values
Due to the growing number of poorly water-soluble drugs, solubility
issues are becoming increasingly important in oral drug delivery. In
that regard, luminal pH is one of the most important parameters since
many drugs are ionisable above or below a certain pH value. Greater
ionisation of the dissolving drug typically facilitates the process of drug
dissolution. Therefore, changes of the luminal pH values may be
translated directly into changes of drug solubility and potentially, into
an altered oral bioavailability. The intake of food or drinks changes the
luminal conditions in the stomach and the small intestine. The resulting
pH profiles in these parts of the human GI tract are highly dynamic and
the result of the complex interplay between the amount and properties
of the ingested contents, oral and gastric secretions, digestion, ab-
sorption and the transfer of material along the GI tract. In Fig. 5, an
exemplary luminal pH profile that was measured after the administra-
tion of the telemetric SmartPill® capsule in the fed state, is depicted
(Koziolek et al., 2015b).
This graph shows that the human stomach is typically characterised
by acidic conditions, whereas in the small intestine, pH values of
Fig. 5. Exemplary luminal pH (black), pressure (red) and temperature (blue)
profiles over time obtained after administration of a telemetric motility capsule
in fed state by subject 9 (GE – gastric emptying, CA – colonic arrival). (For
interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
Reprinted from Koziolek et al., 2015b, with permission from Elsevier.
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pH 6–8 occur. The gastric pH values measured directly after SmartPill
administration under fed conditions are around pH 4 and subsequently,
luminal pH decreases to pH 1, which is more or less equivalent to the
pH value of the gastric secretions. At this time, the gastric contents are
highly diluted by oral and gastric secretions. The re-acidification of the
stomach is illustrated in Fig. 6.
By simply comparing the range of pH values measured in fed state
with range of pH values that are measured in the fasted state, it is
obvious that fasted state pH values cover a similar range (Koziolek
et al., 2015a, 2015b). However, the transit time through the fed sto-
mach is significantly longer and thus, more time is available for drug
dissolution (Koziolek et al., 2014b, 2016). Moreover, the contents are
continuously emptied into the small intestine. Providing that absorp-
tion is faster than precipitation or that certain micellar structures so-
lubilise the drug, the administration of a weakly basic drug after food
intake can lead to positive food effects (increased oral drug bioavail-
ability). Interestingly, various weakly basic drugs (e.g. itraconazole,
erlotinib), for which the gastric pH is expected to be the main reason for
a positive food effect, experience reduced oral bioavailability if the
drug is co-administered with acid-reducing agents. For example, itra-
conazole (pKa= 3.7) experiences a positive food effect, but co-medi-
cation with omeprazole leads to a decrease of the AUC0–24 h by 64%
[75]. Similar effects were also observed for various oral anticancer
drugs (e.g. erlotinib or pazopanib) [17]. However, if precipitation is
much faster than absorption, the pH-shift in the small intestine caused
by the secretion of bicarbonate induces the precipitation of the drug.
Thus, all the benefits in terms of solubility that resulted from a pro-
longed contact with acidic contents in the stomach will be cir-
cumvented. In terms of luminal drug concentrations, the effect of food
components and digestion products on luminal buffer composition in
stomach, upper intestine and proximal colon must be considered as
well. It was shown in in vitro experiments that the buffer species can
affect drug release as well as drug precipitation in the small intestine
(Vertzoni et al., this issue).
As can be seen from Fig. 5, luminal pH values in the small intestine
increases from pH 6–7 in proximal parts to values of pH 7–8 in distal
parts (Koziolek et al., 2015b). Several studies have shown that food
intake can cause minor changes of the intestinal pH value. Directly after
food intake, the luminal pH value in the proximal small intestine can be
around one pH unit lower than in the fasted state, which can be ex-
plained by the emptying of buffered, acidic contents into the duodenum
(McCloy et al., 1984). Thus, drugs with a pKa value in the range of 5–7
may be affected by this luminal pH change, but the relevance of this
effect in terms of food-drug interactions was not shown so far. The pH
values in the colon are highly variable and it seems as if they are not
directly affected by food intake. Therefore, they are not further dis-
cussed at this point. However, the intake of food leads to the gastroileal
reflex which can cause pH changes in the ascending colon (Reppas
et al., 2015).
3.4. Physicochemical aspects of luminal media
The intake of a meal generates physiological responses which lead
to various changes with respect to the physicochemical properties of the
luminal contents (Fig. 7) which can affect intraluminal formulation
performance. Meal-induced changes in the physicochemical character-
istics of intraluminal contents, apart from pH (Section 3.3), are sum-
marised below. It is important to note that relevant changes in stomach
and upper intestine (duodenum and proximal jejunum) to date have
been investigated mainly after administration of liquid meals.
In the stomach, buffer capacity (specifically, the resistance of con-
tent in increasing intragastric pH values) and osmolality are higher in
the fed state (Pentafragka et al., 2018). Due to increased volumes of
gastric contents in the fed state, pepsin levels are only slightly higher
and gastric lipase levels are lower in the fed state (Pentafragka et al.,
2018). However, both show increased activity, due to more favourable
pH values. The altered physicochemical characteristics of gastric con-
tents in the fed state could lead to delayed disintegration of IR products.
Meal-induced delays in tablet disintegration (Kelly et al., 2003) and in
capsule disintegration (Cole et al., 2004; Digenis et al., 2000) have been
reported by using scintigraphic techniques. The formation of a film of
precipitated food components, mainly proteins, around the tablets
which slows water penetration and prevents effective tablet disin-
tegration (Abrahamsson et al., 2004) and meal induced viscosity (Cvijić
et al., 2014) have been speculated as potential reasons, based on in vitro
data.
With regard to intraluminal viscosity, only values for the contents of
the fasted stomach have been reported (Litou et al., 2016; Pedersen
et al., 2013). The limited number of human aspiration studies per-
formed after administration of solid meals and the difficulty to specify
viscosity values of non-Newtonian fluids in highly variable environ-
ment are two potential reasons. Published data suggest that input
viscosity values of the order of 2000mPa s (100 s−1) lead to clinically
important changes in plasma levels of highly permeable compounds
(Carver et al., 1999; Reppas et al., 1993). It should be noted that re-
levant data have been collected by employing a non-digestible, non-
absorbed viscosity inducing agent (hydroxypropyl methylcellulose,
HPMC). The meal that it is typically used in oral drug absorption studies
has a much lower input viscosity, about 430mPa·s (100 s−1) (Klein
et al., 2004). Furthermore, canine data indicate that, after administra-
tion of McDonalds's cheeseburger with French fries and 300mL water
(viscosity of 1310 ± 940mPa·s at 100 s−1, n= 9), the viscosity in the
middle of the canine small intestine becomes 30 ± 50mPa·s (de-
termined at 100 s−1 in 3 dogs, 2–3 administrations per dog)
(Greenwood, 1994); in 2 of the 3 dogs the viscosity was approximately
1mPa s, i.e. similar with that of water (Greenwood, 1994). More data
are needed in order to confirm whether luminal viscosity is an im-
portant parameter to consider when evaluating drug dissolution and
transport in the contents of the small intestine in the fed state.
In the upper intestine (duodenum and upper jejunum), the buffer
capacity (specifically, the resistance of contents in decreasing their pH)
in the fed state is more than double when compared with the buffer
capacity in the fasted state (Pentafragka et al., 2018). Unlike in the
Fig. 6. Re-acidification of the stomach over a period of 5 h after intake of the
FDA standard breakfast. Each box represents a 5min interval. Box: 50%,
whisker: 10–90%, square: mean, asterisks: max/min; n= 16.
Reprinted from Koziolek et al., 2015b, with permission from Elsevier.
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fasted state, duodenal contents in the fed state are hyperosmotic, in
most cases. A 5-fold increase of phospholipase A2 secretion and at least
5-fold increase of pancreatic lipase secretion are observed in the fed
state. Bile salts and phospholipid concentrations are highly variable
however, on average, greater than in the fasted state. The bile salt/
phospholipid ratio remains fairly constant (about 3.4), significantly
lower than that in the fasted state (about 11.5) (Pentafragka et al.,
2018). Changes in luminal cholesterol levels tend to echo those of the
bile salts and phospholipids, with which they coexist in the form of
mixed micellar structures. Depending on the dissolving particle size and
the lipophilicity of the drug, changes in colloidal species composition
and concentrations in the lumen induced by food intake (Vertzoni et al.
this issue) could impact drug release and dissolution by reducing the
surface tension and facilitating wetting and by inducing solubilisation
effects. For drugs being classified as poorly soluble, highly permeable
according to Biopharmaceutical Classification System (BCS Class II
drugs), the increased presence of solubilising agents in the upper GI
lumen after meal consumption generally enhances the dissolution of the
dose. However, the potentially decreased diffusivity of colloidal solu-
bilising species may adversely affect the absorption process (Vertzoni
et al., 2012). For BCS Class IV drugs (poorly soluble and poorly
permeable), the impact of extensive luminal solubilisation in the fed
state is even less straightforward as, in this case, transport through the
mucosa may also be influenced by changes in the membrane fluidisa-
tion (which may be induced by the interaction with surfactants) or the
activity of membrane transport carriers (Porter et al., 2007).
In the lower intestine (distal ileum and proximal colon), most data
have been collected 5 h after the administration of high calorie, high fat
meal, i.e. about the time which drugs administered as IR products or
multi-particulate MR products are expected to reach the region, after
oral administration. The buffer capacity is significantly higher in the fed
state (Pentafragka et al., 2018). Contents are hypo-osmotic in the fed as
in the fasted state with values lower than in the fasted duodenum. Bile
salt concentrations are much lower than in the upper intestine, re-
gardless the prandial state. In the ascending colon, bile salt contents are
higher 5 h after administration of the high-caloric, high-fat meal than
5 h after a glass of water in fasted adults (Pentafragka et al., 2018).
High variability in composition of contents makes difficult to detect
significant differences other luminal substances between prandial con-
ditions, if any.
3.5. Interaction of food with intestinal microbiota
100 trillion microbes present in the gut lumen secrete a diverse
array of enzymes capable of metabolising various drugs, including their
reduction, hydrolysis, removal of succinate group, dehydroxylation,
acetylation, deacetylation, cleavage of N-oxide bonds, proteolysis, de-
nitration, amine formation and hydrolysis of amide linkages, deconju-
gation, thiazole ring-opening, isoxazole scission, deglycosylation, and
N-demethylation. To date, at least thirty commercially available drugs
are identified as substrates for these bacterial enzymes and thanks to
modified release systems and drugs with poor solubility and/or poor
permeability (Dvorackova et al., 2013), many others are likely to be
discovered (Sousa et al., 2008).
Furthermore, pro-drugs poorly absorbed in the stomach and small
intestine as well as drug delivery systems specifically targeting the
colon (e.g. drug delivery systems based on polysaccharide substrates of
colonic bacteria) are designed to release the pharmacologically active
substance by microbial activity (Sousa et al., 2014). It is therefore now
increasingly accepted that the gut microbiota influences drug bioa-
vailability, pharmacokinetics, efficacy or adverse effects (Enright et al.,
2016). Indeed, administration of probiotics led to increased bioavail-
ability of amiodarone in male Wistar rats (Matuskova et al., 2014), of
gliclazide in diabetic rats (Mikov et al., 2018) and of amlodipine in
rabbits (Saputri et al., 2018). To the best of our knowledge, almost no
human data are available to date. The producers of probiotics only
recommend a 2 h-interval between their administration and adminis-
tration of antibiotics (Mikawlrawng et al., 2016). In other cases, mi-
crobes seem to lower the bioavailability of certain drugs. For instance,
the increase in tacrolimus dosing in kidney transplant patients was
positively correlated with the increased Faecalibacterium prausnitzii
abundance in faecal samples in the first week of transplantation (Lee
et al., 2015). Other examples can be found in a review by Enright et al.
that was published in 2016 (Enright et al., 2016).
Fig. 7. Major physiological responses and changes in the luminal physicochemical characteristics after meal intake. Data in distal ileum and proximal colon refer to
about 5min after meal intake.
Adapted from O'Shea et al., 2018.
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Composition of the gut microbiome, nutritional status, age, disease
and the co- or pre-administration of other drugs are environmental
(epigenetic) factors that form the metabolic phenotype and that are
responsible for inter-individual variation in drug effects (Clayton et al.,
2006). The composition of colonic microbiota is, in turn, highly vari-
able and dependent on different factors, including age (Margalef et al.,
2016; Merchant et al., 2016), ethnicity (Lee et al., 2017; Stearns et al.,
2017), diseases such as cirrhosis or Crohn's disease (Enright et al.,
2017) or use of probiotics (Matuskova et al., 2014), antibiotics or
specific inhibitors (Enright et al., 2016). An important factor which
determines the structure of gut microbial community is the individual's
diet as the gut microbiome can rapidly respond to a changed diet
(David et al., 2014). Indeed, even short-term consumption of ex-
clusively animal or plant diets have an important impact on gut mi-
croflora composition and overwhelmed inter-individual differences in
microbial gene expression. The animal-based diet increased the pro-
portion of bile-tolerant microbes (Alistipes, Bilophila, and Bacteroides)
and decreased the levels of plant polysaccharides metabolising Firmi-
cutes (Roseburia, Eubacterium rectale, and Ruminococcus bromii) (David
et al., 2014). On the other hand, a diet low in fermentable oligo-
saccharides, disaccharides, monosaccharides and polyols (FODMAPs)
was associated with reduced Bifidobacterium and Actinobacteria in pa-
tients with irritable bowel syndrome (Bennet et al., 2018).
Altered composition of intestinal microbiome affects the pharma-
cokinetics of drugs mostly by the specific metabolic activity of microbes
which differ among various microbial species (Enright et al., 2016).
Drug metabolism by the intestinal microbiome is likely to result in a
different metabolite profile than that formed by host cells. This might
potentially result in different levels of activation or inactivation of the
pharmacological and/or toxicological actions of the molecule(s) when
compared with that obtained by the host cells (Kang et al., 2013). The
metabolite formed can be less active than the parent compound or toxic
(Sousa et al., 2008). The role of microbiota in food-drug interactions,
besides the direct biotransformation of the drug by the microbes, is
mediated by various additional mechanisms. One of them involves the
role of bile salts, their deconjugation by microbial bile salt hydrolase
(BSH) and hydroxylation by 7α-dehydroxylase. While the former in-
fluences micellar solubilisation capacity for some poorly water-soluble
drugs, the latter significantly affect the solubilisation capacity of bile
salt micelles (Enright et al., 2017). This process is further affected by
food related postprandial increase in bile secretion into the intestine
(Lentz, 2008). Another aspect is the microbial production of short chain
fatty acids and especially butyrate, which improves epithelial barrier
integrity (Geirnaert et al., 2017). In addition, metabolites formed by the
microbiota can affect drug transport; treatment of healthy rats with
probiotics upregulate the mucosal efflux drug transporters (MRP2) that
control gliclazide transport. In contrast, in diabetic rats, treatment with
probiotics increased fluxes of gliclazide through normalisation of the
functionality of the drug transporters ex vivo (Al-Salami et al., 2008).
As the role of gut microbiome on food drug interactions has been
explored only in recent years, many other aspects are likely to be dis-
covered in the future. In any case, the contribution of intestinal mi-
croorganisms to the determination of drug bioavailability and phar-
macokinetics should now be taken into consideration in drug
development process (Enright et al., 2017).
4. Food effects on drug absorption
Following physical and chemical processing of ingested food, nu-
trient molecules are presented to the intestine to be absorbed and fur-
ther metabolised. Absorption can occur passively (through concentra-
tion gradients) or actively (by transporters). Enterocytes contain a high
variety of transporters and enzymes specialised to absorb, expel and
metabolise a high variety of nutrients. As drug molecules can use
identical pathways to reach the systemic circulation, food-drug inter-
actions at the level of the intestinal monolayer are inevitable. Here, we
briefly illustrate these interactions using some key examples; for a de-
tailed review on the mechanisms underlying food-drug interactions, we
refer to the excellent review written by Won et al. (2012).
4.1. Interaction with uptake and efflux transporters
Food-drug interactions often originate from drug and nutrient mo-
lecules competing for the same route of transport. The list of uptake and
efflux transporters in the human intestine (and other organs) is ex-
tensive, a comprehensive list can be found in a research article by
Hilgendorf et al. (2007)). Several groups have reviewed literature re-
garding potential food-drug interactions with specific focus on trans-
porter interactions (Custodio et al., 2008; Nakanishi and Tamai, 2015;
Rodríguez-Fragoso et al., 2011).
4.1.1. Organic anion transporting polypeptides (OATP)
Organic anion transporting polypeptides (OATP) are a family of
uptake transporters of proteins, which can be found in both, liver and
intestine (Niemi, 2007). Specifically, OATP2B1 (and to a lesser extent
OATP1A2) are present in the apical membrane of intestinal enterocytes.
OATP2B1 is recognised as highly involved in nutrient and drug ab-
sorption from the digestive tracts in humans. Although the precise
mechanism is unknown, a pH-dependence is often suggested
(Kobayashi et al., 2003; Nozawa, 2003). OATP transporters are in-
volved in transport of endogenous substrates including bile acids,
thyroid hormones, prostaglandins and bilirubin glucuronides
(Hagenbuch and Meier, 2003; Shitara et al., 2013). Common drug
substrates include statins, protease inhibitors, fexofenadine, mid-
azolam, montelukast, aliskiren and talinolol (Nakanishi and Tamai,
2015; Shitara et al., 2013; Tamai, 2012). Multiple studies in humans
have proven a clinically significant reduction in intestinal absorption of
these drugs when ingested with grapefruit, orange and apple juices
(Imanaga et al., 2011; Mougey et al., 2009; Shirasaka et al., 2013;
Tapaninen et al., 2010). A large variety of flavonoids present in these
juices are considered responsible for this activity. In vitro, flavonol
glycosides and catechins present in herbal extracts and green tea have
been observed to inhibit OATP1A2 as well (Fuchikami et al., 2006; Roth
et al., 2011).
4.1.2. Oligopeptide transporter (PEPT1)
Oligopeptide transporters are mainly found in the apical membranes
of intestinal epithelial cells and are known to participate in the ab-
sorption of di- and tri-peptides and peptide-like drugs. These trans-
porters use a proton gradient as a driving force and recognise a broad
range of oligopeptides (Smith et al., 2013). The most common drug
substrates include β-lactam antibiotics, cephalosporines, L-dopa pro-
drugs and some ACE-inhibitors (Brandsch, 2013; Brodin et al., 2002).
Theoretically, an interaction could occur when an oligopeptide com-
petes with a peptidomimetic drug, although clinically relevant inter-
actions have not been reported in human subjects (Nakanishi and
Tamai, 2015). Tsui et al. observed that Parkinson patients performed
better on a low-protein diet compared to a high protein diet, although
this could not be correlated to systemic L-dopa levels (Tsui et al., 1989).
Furthermore, fasting has been reported to increase PEPT1 transcription
in mice and zebrafish, theoretically implying increased absorption of
peptidomimetic drugs (Koven and Schulte, 2012; Nässl et al., 2011).
4.1.3. P-glycoprotein (P-gp)
P-glycoprotein is the most studied efflux transporter and a known
mediator for clinically relevant food-drug interactions. This transporter
can be found in a broad range of tissues although its pronounced in-
testinal presence is most relevant in the context of food-drug interac-
tions (Marchetti et al., 2007). Although the exact mechanisms of action
remain to be elucidated, ATP hydrolysis is known to be involved. A
broad range of substrates has been identified including antiarrhythmics,
antihypertensive drugs, cyclosporine, tacrolimus and morphine
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(Nakanishi and Tamai, 2015). Furanocoumarins and flavonoids present
in a large variety of fruits and vegetables are considered the main
dietary inhibitors of P-gp. In vitro, common lipid degradation products
and sodium taurocholate (bile salt) have been demonstrated to inhibit
P-gp activity (Ingels et al., 2004; Konishi et al., 2004a, 2004b). For an
extended list of P-gp substrates and inhibitors we refer to Didziapetris
et al. (2003) and Fenner et al. (2009). Several clinically relevant in-
teractions have been reported when grapefruit juice is ingested with
known P-gp substrates (see Section 7.1). Furthermore, extracts of St.
John's wort, available over-the-counter, can induce P-gp transporter
activity affecting drug absorption of digoxin, indinavir and cyclosporine
(Zhou et al., 2004). A noteworthy example is fexofenadine, a substrate
for both OATP (uptake) and P-gp (efflux). The overall bioavailability of
fexofenadine is decreased when ingested with a fruit juice due to a more
pronounced inhibition of OATP relative to P-gp (Dresser et al., 2002,
2005).
4.1.4. Other efflux transporters
Besides P-gp, other efflux transporters including multidrug re-
sistance associated proteins (MRPs) and breast cancer resistance protein
(BCRP) are expressed in the apical membrane of intestinal cells. MRPs
are more commonly found in the liver although some variants can be
found at the basolateral side of intestinal epithelial cells transporting
molecules to the portal vein. In general, MRP effluxes conjugated me-
tabolites including glutathione, glucuronides or sulphate adducts from
the enterocyte (Keppler, 2011). Flavonoids are common inhibitors of
these transporters. Van Zanden et al. found that phase II metabolites of
quercetin (especially glucuronides) are potent MRP inhibitors in vitro
(van Zanden et al., 2007). Chalet et al. observed rapid formation and
apical excretion of these metabolites in the small intestine of human
volunteers after ingestion of quercetin (Chalet et al., 2018). Though
these observations suggest possible food-drug interactions, no relevant
interactions involving MRPs have been reported (Takano et al., 2006).
Likewise, BCRP transports conjugated metabolites, however in vivo,
conjugated BCRP substrates are limited (Leslie et al., 2005). Some
common BCRPs substrates include conjugated statins, steroid hor-
mones, folic acids and vitamins B2 and K3 (Nakanishi and Ross, 2012).
Deviating pharmacokinetic profiles of these drugs have been linked to
genetic polymorphisms of BCRP in individuals, albeit no relevant food-
drug interactions have been reported (Nakanishi and Tamai, 2015;
Takano et al., 2006).
4.2. Interaction with intestinal monolayer: membrane fluidity
Molecules that increase the intestinal monolayer fluidity can theo-
retically influence drug absorption as an increase in fluidity can in-
crease the diffusion rate of some drugs (Friedlander et al., 1990). Fla-
vonoids, cholesterol and α-tocopherol have all been shown to partition
into cellular membranes thereby increasing their fluidity (Arora et al.,
2000). However, the clinical relevance of these in vitro findings has not
been demonstrated yet.
4.3. Interaction with intestinal drug-metabolising enzymes
Human small intestine epithelial cells (enterocytes) are typically the
first site of drug metabolism of orally administered drugs. As can be
seen from Fig. 8, CYP3A and CYP2C9 are the major CYP enzymes in the
small intestine, accounting in total for> 95% of the total CYP content
(Paine et al., 2006). However, it should be noted that the distribution of
drug-metabolising enzymes can vary along the small intestine and that
CYP abundance in the small intestine differs strongly from CYP abun-
dance in the liver (Drozdzik et al., 2018; Fritz et al., 2018).
The intestinal metabolism by CYP3A enzymes contributes to the
first-pass metabolism of many drugs such as cyclosporine, verapamil,
felodipine, midazolam, tacrolimus, simvastatin or nifedipine and the
effect can be augmented by inducers of these enzymes such as
rifampicin (Galetin et al., 2010; Glaeser et al., 2004; Gorski et al., 2003;
Holtbecker et al., 1996; Kyrklund et al., 2000; Peters et al., 2016;
Tannergren et al., 2004; Uesugi et al., 2006; Wu et al., 1995). For
various drugs, the intestinal metabolism by CYP3A4 seems to be even
more important than hepatic metabolism in the overall first-pass effect
(Galetin et al., 2010; Lin, 2006).
The most important food-drug interactions mediated by inhibition
or down-regulation both of phase I and phase II intestinal drug meta-
bolism enzymes as well as intestinal transporters by food constituents
including fruit juices, phenolic and polyphenolic compounds were re-
viewed in 2012 by Won and colleagues (Won et al., 2012). The most
important food-drug interactions with grapefruit juice and some poly-
phenolic compounds are also mentioned in chapters 7.1.1. and 7.4.1. of
this review.
The phase I enzymes in the enterocytes mediate various drug-drug
but also food-drug interactions (Won et al., 2012). In this respect, citric
fruit juices (in particular grapefruit juice, see also Section 7.1) have
been shown to increase the systemic exposure of several CYP3A sub-
strates in humans. In most cases, the effect is limited to oral (as opposed
to i.v.) administration, indicating the importance of intestinal CYP3A in
mediating food-drug interactions. Considering the extent of the ob-
served effect, adverse events cannot be ruled out for some classes of
drug (e.g. muscle pain with statins). While the possible role of alcoholic
beverages and green tea in CYP3A-mediated food-drug interactions has
been reported as well, the clinical relevance remains uncertain.
Overall, multiple studies have demonstrated food-drug interactions
at the level of the intestinal monolayer. In clear cases, these interactions
will affect systemic drug pharmacokinetics potentially imposing dan-
gerous scenarios for drugs with a narrow therapeutic index. The po-
tential for food-drug interactions to cause adverse events led the FDA to
publish multiple guidances, encouraging the pharmaceutical industry
to research interactions during drug development (Huang et al., 2008).
It should be noted, however, that robust research in this field is often
hindered by (i) the complex nature of food and drinks, making it hard to
understand food-drug interactions at a molecular level, (ii) the in vitro-
in vivo discrepancy, questioning the clinical relevance of several in vitro
findings, and (iii) the impact of genetic polymorphisms for intestinal
transporters and enzymes (Yoshida et al., 2013), leading to a highly
variable impact of food-drug interactions.
5. Food effects on drug distribution
As seen in the preceding sections, food induces myriad changes in
the gastrointestinal tract that can increase, decrease, delay or accelerate
the intestinal absorption of a drug depending on the physicochemical
properties of the drug (Carver et al., 1999). Many studies in the
Fig. 8. The abundance of drug-metabolising enzymes in the proximal small
intestine (n= 31).
Adapted from Paine et al., 2006.
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literature have focussed on meal-induced changes in gastrointestinal
drug absorption. The fed state can, however, also influence the route of
drug transport from the intestine to the blood circulation (lymph versus
portal vein), drug distribution to organs and tissues including target and
off-target sites, and organs of elimination. This section discusses food-
induced changes in drug distribution and their clinical ramifications.
5.1. Lymphatic drug transport
Following absorption, the majority of drugs are transported from
the intestine to the systemic blood circulation through the mesenteric
capillaries and veins, then via the portal vein to the liver before
reaching the general circulation. However, the intestinal epithelium
also contains a rich network of lymphatic vessels (see Fig. 9) (Bernier-
Latmani and Petrova, 2017; Trevaskis et al., 2008, 2015).
Each intestinal villi has one or two blind-ended lacteals through
which lymph flows to pre-collecting, then collecting mesenteric lymph
vessels and lymph nodes, before eventually joining the thoracic lymph
duct. The thoracic lymph empties directly into the systemic circulation
via the subclavian vein thus avoiding passage through the liver (unlike
portal vein blood). Most drugs, however, are not transported in sig-
nificant quantities via the lymphatic vessels as the flow rate of mesen-
teric lymph fluid is 500–1000 fold lower than the flow rate of blood
through the portal vein (Charman and Stella, 1986; Trevaskis et al.,
2008, 2015). In contrast, dietary lipids and some highly lipophilic
compounds, including highly lipophilic drugs and/or prodrugs (typi-
cally those with logP>5 and long chain triglyceride solubility> 50
mg/kg and/or very high affinity for chylomicrons such as halofantrine
(Khoo et al., 2003), testosterone undecanoate (Shackleford et al., 2003)
and methylnortestoerone undecanoate (White et al., 2009), moxidectin
(Lespine et al., 2006), CP532,623 and CP524,515 (Trevaskis et al.,
2010b), Org45697 and Org46035 (Caliph et al., 2009), cannabinoids
(Zgair et al., 2017), dexanabinol and PRS-211,220 (Gershkovich et al.,
2007a)) may be transported from the intestine via the lymphatics
(Charman and Stella, 1986; Lawless et al., 2015; Trevaskis et al., 2008,
2010c, 2015). This is mediated by drug association with the lipid-rich
lipoproteins (primarily chylomicrons, CMs) that are assembled in the
enterocyte from dietary and endogenous lipids. CMs are transported
from the intestine via the lymphatics as the blood vessel endothelium is
less permeable than the lymphatic endothelium, precluding the access
of CMs that can be up to 1000 nm in diameter (Dixon, 2010; Randolph
and Miller, 2014; Trevaskis et al., 2008, 2015). In contrast, the initial
lymphatics and lacteals contains wide gaps between endothelial cells
and also potentially active transport pathways that facilitate the entry
of large assemblies such as CMs (Dixon, 2010; Randolph and Miller,
2014; Trevaskis et al., 2008, 2015).
The total mass of the drug that is absorbed and transported from the
intestine via the portal vein and lymphatic system combined can be
altered by food induced changes to the rate and/or extent of drug ab-
sorption via the mechanisms outlined earlier in this review. For highly
lipophilic drugs, food may also affect the route of drug transport from
the intestine to blood circulation (i.e. proportional transport via the
lymph vs portal vein). The lipid component of food (both lipid quantity
and type), in particular, influences intestinal lymphatic drug transport
as some dietary lipids stimulate intestinal CM formation and thus in-
creases in lymphatic lipid and drug transport (Trevaskis et al., 2008,
2015). For instance, post-prandial administration of highly lipophilic
drugs such as halofantrine, methylnortestosterone undecanoate,
CP532,623 and CP524,515 to greyhound dogs markedly increases in-
testinal lymphatic drug transport relative to administration in the fasted
state (Khoo et al., 2002; Trevaskis et al., 2010b; White et al., 2009). For
these compounds, administration with even a small quantity of lipid (in
a formulation or partial meal) is sufficient to support a substantial in-
crease in lymphatic lipid and drug transport, with drug transport in
lymph directly related to the quantity of lipid consumed (Khoo et al.,
2003; Trevaskis et al., 2010b; White et al., 2009). In addition to
quantity, the type of lipid in the meal influences the extent of lymphatic
drug transport. This reflects the fact that long chain lipids (such as those
found in in olive oil, soybean oil, animal fats etc.), but not short or
medium chain length lipids (such as those found in higher concentra-
tion in coconut oil), are assembled into CMs and transported from the
intestine via lymph (Caliph et al., 2000; Trevaskis et al., 2013). Dif-
ferences in lipid saturation can also influence lymphatic lipid and drug
transport (Holm et al., 2001). Mono- and poly- unsaturated lipids
promote greater increases in CM formation and lymphatic lipid trans-
port than equivalent chain length saturated lipids and may therefore be
expected to more efficiently promote lymphatic drug transport.
Overall, intestinal lymphatic transport of highly lipophilic drugs
may therefore vary depending on the type and quantity of lipid in in-
gested food and will be particularly increased when drug is adminis-
tered around the same time as a long chain lipid-rich meal (Khoo et al.,
2002; Trevaskis et al., 2010b; White et al., 2009). Recent studies in
animal models have demonstrated that increases in lymphatic drug
transport can alter drug metabolism (Shackleford et al., 2003; Trevaskis
Fig. 9. Following oral administration, the majority of drugs are transported from the intestine to the systemic blood circulation through the mesenteric capillaries
and veins (i.e. blood vessels) (1), then via the portal vein to the liver before reaching the general circulation (2). In contrast, dietary lipids are assembled into
lipoproteins (yellow circles) that are transported from the intestine via the lymphatic vessels (3). Similarly, highly lipophilic drugs and/or prodrugs can associate with
the lipid-rich lipoproteins during passage across enterocytes and subsequently be transported from the intestine via the lymphatic vessels (4). Co-administration with
food derived lipids tends to increase lymphatic drug transport. The lymphatic vessels draining the intestine flow through one or more lymph nodes before joining the
thoracic lymph duct which empties lymph directly into the blood circulation at the subclavian vein above the heart. This avoids passage through the liver and
promotion of lymphatic drug transport (e.g. via co-administration with food/lipids) can therefore reduce first-pass drug metabolism and enhance drug bioavailability
(5). Upon entry into the systemic blood circulation, drugs can reversibly associate with plasma proteins (blue stars) or lipoproteins (yellow circles) (6). Only free drug
is readily able to extravasate from the blood vessels and cross cell membranes. Food induced changes in drug binding to plasma proteins and/or lipoproteins can
therefore alter drug disposition to organs and tissues, and drug clearance (by affecting drug uptake into clearance organs). (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
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et al., 2006, 2009) and drug disposition (Caliph et al., 2013) which can
subsequently impact drug bioavailability (Shackleford et al., 2003;
Trevaskis et al., 2006, 2009) and potentially drug efficacy/safety pro-
files (Trevaskis et al., 2010a; Zgair et al., 2017). Promotion of intestinal
lymphatic transport reduces first pass hepatic metabolism as the lymph
empties directly into the blood circulation without first passing through
the liver (as above) (Khoo et al., 2003; Shackleford et al., 2003;
Trevaskis et al., 2009; White et al., 2009). First pass metabolism in the
enterocyte may also be reduced through drug sequestration into lipo-
proteins thus reducing drug access to metabolic enzymes (Trevaskis
et al., 2006). Overall, the reduction in metabolism will increase drug
bioavailability and potentially therefore influence therapeutic effect.
Furthermore, emerging evidence primarily in animal models suggests
that promotion of drug transport through the lymph can increase the
efficacy of drugs with lymph resident targets such as im-
munomodulators (Trevaskis et al., 2010a; Zgair et al., 2017), anti-
cancer drugs (Kaminskas et al., 2013; Ryan et al., 2014) and anti-in-
fectives (Chan et al., 2017; Fletcher et al., 2014; Trevaskis et al., 2015).
By enabling the administration of lower drug doses to achieve similar
therapeutic effects this could potentially enable a reduction in drug
toxicity. Finally, entry into the systemic blood circulation within lymph
lipid-rich lipoproteins can alter drug disposition and clearance (Caliph
et al., 2013) thus impacting drug efficacy and toxicity. This is described
in the following section.
5.2. Binding to lipoproteins
Lipoproteins are macromolecular vehicles that transport lipids and
lipophilic molecules (including some drugs such as halofantrine, cy-
closporine A, amiodarone, amphotericin B, nystatin, eritoran, cloza-
pine, haloperidol, paclitaxel etc. (Wasan et al., 2008)) through the
aqueous environment of the blood circulation and the lymphatic system
(Randolph and Miller, 2014; Wasan et al., 2008). There are four main
classes of lipoproteins (in order of decreasing size/core lipid content,
and increasing density); CMs, very low density lipoproteins (VLDL), low
density lipoproteins (LDL) and high density lipoproteins (HDL). CMs are
only assembled in the intestine whereas the other lipoproteins are as-
sembled in the liver with lesser amounts released by the intestine. The
main role of CM and VLDL is to transport triglycerides to tissues
whereas LDL transport cholesterol to tissues, and HDL return choles-
terol from tissues to the liver for excretion (Randolph and Miller, 2014;
Wasan et al., 2008).
Lipoproteins have a core composed of neutral lipids (triglycerides,
cholesterol esters) and a surface composed of amphiphilic lipids
(phospholipids, cholesterol) and apo-proteins (Randolph and Miller,
2014; Wasan et al., 2008). Lipophilic drugs can associate with either the
core or surface of lipoproteins depending on their physicochemical
properties (Wasan et al., 2008). Association may occur during intestinal
absorption, as described above for drugs that are lymphatically trans-
ported (Gershkovich and Hoffman, 2007; Porter et al., 2007). Alter-
natively, association may occur upon drug entry into the blood circu-
lation (Gershkovich and Hoffman, 2007; Wasan et al., 2008), in an
analogous manner to drug binding to plasma proteins. The association
with lipoproteins reduces the free (unbound) fraction of drug present in
blood/plasma (Gershkovich and Hoffman, 2007; Wasan et al., 2008). In
general, free (unbound) drug is more available to diffuse across cell
membranes and to enter organs and tissues. In this way, binding to
lipoproteins may reduce the availability of free drug to distribute to
tissues thus reducing the volume of distribution (Vd) and also clearance
(Cl) by reducing uptake into the liver and/or kidney (Gershkovich and
Hoffman, 2007; Mehvar, 2005; Patel and Brocks, 2009). The extent of
change to drug Vd and Cl with change in free drug fraction will,
however, depend on whether the drug has a low or high Vd or Cl.
Generally, a reduction in the free fraction leads to a greater reduction in
Vd or Cl for drugs with high Vd or low intrinsic Cl, respectively. The
reason for this is well summarised in previous reviews (Huang and Ung,
2013; Mehvar, 2005; Wasan et al., 2008).
Multiple receptors and enzymes facilitate lipid transfer between
different lipoprotein types and from lipoproteins into tissues to be
stored or used as an energy source (particularly metabolic tissues such
as liver, muscle and adipose tissue) (Randolph and Miller, 2014; Wasan
et al., 2008). Association with lipoproteins may thus result in increases
or decreases in drug disposition to specific tissues by promoting inter-
action with specific lipoprotein transport pathways (Caliph et al., 2013;
Gershkovich and Hoffman, 2007; Patel and Brocks, 2009; Wasan et al.,
2008; Yamamoto et al., 2017). Currently these changes cannot be ac-
curately predicted for a given drug and must be determined empirically.
For an excellent summary of these effects see reviews by Wasan et al.
(2008) and Patel and Brocks (2009).
Following a meal, the distribution of lipids across different lipo-
protein subclasses, and the metabolism and tissue uptake of lipoprotein
lipids is altered (Wasan et al., 2008). In particular, the concentration of
lipid-rich lipoproteins (CM and VLDL) in the blood circulation increases
and the lipids in these lipoproteins are directed toward storage tissues
such as adipose tissue and to a lesser extent muscle (Gershkovich and
Hoffman, 2007; Ooi et al., 2015; Wasan et al., 2008). These changes are
dependent on the type of meal and also a range of inter-individual
factors such as type of food and diet, race, sex, and presence of health
conditions such as dyslipidaemia and metabolic diseases (which can
exaggerate meal induced increases in plasma lipids) (Ooi et al., 2015;
Wasan et al., 2008). Given that food has a range of effects on lipopro-
tein metabolism and transport, and that lipoprotein association can
increase or decrease drug Vd and Cl, and alter tissue disposition, it is
perhaps not surprising that co-administration with food has been found
to have a range of different effects on tissue disposition, Vd and Cl of
lipoprotein associated drugs (Brocks et al., 2006; McIntosh et al., 2004;
Patel and Brocks, 2009; Shayeganpour et al., 2005, 2008; Wasan et al.,
2008). Less effort has been directed toward assessment of whether these
changes in disposition may impact drug activity, however, a limited
number of studies have demonstrated that food induced changes in li-
poprotein-drug binding and distribution can impact pharmacodynamics
(i.e. efficacy and/or safety profiles) (Gershkovich et al., 2007b;
McIntosh et al., 2004; Patel and Brocks, 2010).
5.3. Plasma protein binding
Albumin is the most abundant plasma protein (concentration
3.5–5 g/dL) and the most common protein to which drugs bind in
plasma (Ascenzi et al., 2014; Yamasaki et al., 2013). Alpha-1 acidic
glycoprotein (AAG), although present in much lower concentrations
than albumin (0.04–0.1 g/dL), is the second main plasma protein that
binds drugs (Huang and Ung, 2013; Israili and Dayton, 2001). Several
other proteins have specific affinities for certain endogenous substances
and may bind to specific drugs (Ascenzi et al., 2014; Mehvar, 2005).
Albumin has the capacity to bind a range of endogenous and exo-
genous compounds including fatty acids, metabolites, hormones and
many acidic (anionic) drugs. The multi-domain nature of albumin en-
ables it to bind to a large range of molecules including up to the
equivalent of nine fatty acid molecules at a time. There are two main
binding sites for drugs on albumin – site I (also called the warfarin
binding site) and site II (the benzodiazepine binding site). The structure
of albumin and the nature of its ligand binding pockets have been ex-
cellently reviewed (Ascenzi et al., 2014; Yamasaki et al., 2013).
AAG on the other hand displays a preference for binding lipophilic
bases (cationic) and neutral drugs (Huang and Ung, 2013; Israili and
Dayton, 2001). AAG is a glycoprotein with a single binding pocket re-
sponsible for binding most drugs (Huang and Ung, 2013; Israili and
Dayton, 2001). Since AAG is present at much lower concentrations in
plasma and displays a single major binding pocket, binding to AAG is
more readily saturable with increases in drug concentration than
binding to albumin (Ascenzi et al., 2014; Huang and Ung, 2013; Israili
and Dayton, 2001). Similarly, there is more likely to be competitive
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displacement of drug binding to AAG, when compared with albumin,
via binding of other endogenous or exogenous molecules (Ascenzi et al.,
2014; Huang and Ung, 2013; Israili and Dayton, 2001). For albumin,
drug binding can also be altered through allosteric modulation by
molecules binding at an alternate site to the drug (Ascenzi et al., 2014;
Yamasaki et al., 2013).
As described above for binding to lipoproteins, changes in drug
binding to plasma proteins and thus free (unbound) drug concentra-
tions present in the plasma alter drug availability to transfer to tissues
as free drug is more readily able to extravasate and cross cell mem-
branes (Ascenzi et al., 2014; Huang and Ung, 2013; Israili and Dayton,
2001; Mehvar, 2005). Increases (or decreases) in drug binding to
plasma proteins can thus alter drug tissue disposition patterns, reduce
(or increase) drug Vd and Cl. The extent of change to Vd and Cl depends
on the properties of the drug as described above for lipoprotein binding
(Ascenzi et al., 2014; Huang and Ung, 2013; Israili and Dayton, 2001;
Mehvar, 2005). Alterations in drug disposition and Cl may therefore
ultimately influence the ability of drugs to access target and off-target
sites and thus therapeutic effect.
Food effects on plasma protein binding have not been explored in
detail in the literature. Changes in nutrition status can alter albumin
and AAG concentrations. Malnutrition and cachexia can reduce al-
bumin and AAG concentrations, whereas a high protein diet may in-
crease plasma protein concentrations (Ascenzi et al., 2014; Huang and
Ung, 2013; Israili and Dayton, 2001; Yamasaki et al., 2013). Dietary
components and metabolites could also potentially impact drug binding
to plasma proteins (Ascenzi et al., 2014; Huang and Ung, 2013; Israili
and Dayton, 2001; Yamasaki et al., 2013). For example, fatty acids are
highly bound to albumin and increases in fatty acid concentration can
allosterically modulate the binding of drugs to albumin (Anguizola
et al., 2013; Yamasaki et al., 2017). Changes in blood glucose con-
centration, as seen in diabetes, also modulate albumin glycosylation
and drug binding (Anguizola et al., 2013; Baraka-Vidot et al., 2015).
However, the clinical relevance of diet/food induced changes in drug
binding has not been clearly demonstrated. In general, despite the in-
fluence that plasma protein binding has on the disposition, Cl and effect
of drugs, the risk of clinically relevant interactions via food-induced
changes in drug binding to plasma proteins is considered low (Ascenzi
et al., 2014; Huang and Ung, 2013). This is particularly the case be-
cause transient increases in drug binding to plasma proteins after a
meal typically lead to transient increases in the free drug concentration
in plasma followed by a rapid reduction in free drug concentration due
to compensatory changes to drug Cl and Vd. Change in plasma protein
binding will, however, be most important for highly bound drugs (un-
bound fraction<1%) that have a narrow therapeutic window, parti-
cularly where Cl is high and therefore changes to free concentration in
the plasma do not stimulate significant compensatory changes to
clearance.
6. Food effects on drug metabolism and elimination
Numerous studies indicate that constituents of food can modulate
the activity of drug-metabolising enzymes and drug transporters (Won
et al., 2012). However, translation of in vitro data to the clinic is not
always clear (Farkas and Greenblatt, 2008; Harris et al., 2003; Sprouse
and van Breemen, 2016). Probably the most prominent example of
proven clinical relevance is the inhibition of the metabolism of CYP3A
substrates by grapefruit juice, which is also reported later in this re-
view. Other foods which have been reported to inhibit CYP3A meta-
bolism include Seville orange juice (Edwards et al., 1999) and red wine,
although in the latter case the extent of the interaction is smaller than
that due to grapefruit juice (Offman et al., 2001). Clinically relevant
interactions via CYP3A may also result from the consumption of food
constituents which are inducers of CYP3A enzymes. For example, St
John's wort is a herbal dietary supplement that results in decreased
bioavailability of CYP3A substrates and can lead to the need for dosage
adjustments in certain drugs such as cyclosporine and indinavir. In
addition, garlic has been shown to reduce exposures of saquinavir
(Piscitelli et al., 2002), a drug which is highly extracted by first pass
metabolism in the gut. Indeed, the modulation of pharmacokinetics of
CYP3A4 substrates by food constituents is largely linked to the high
intestinal expression of this enzyme which can result in potential for
significant impact on bioavailability as well susceptibility to modula-
tion by food constituents. Intestinal expression of other CYP enzymes is
lower relative to CYP3A, however certain UDP-glucuronosyl-
transferases (UGT) isoforms are also highly expressed and play a role in
reducing oral bioavailability of drugs such as raloxifene (see chapter
4.4) (Nakamori et al., 2012). Therefore, the potential for food drug
effects when raloxifene is taken with potent inhibitors of UGT exists and
has been explored in vitro (Gufford et al., 2015) although clinical evi-
dence is so far lacking. In addition, inhibition of drug transporters,
including P-gp and OATPs, has been identified as a potential cause of
food effects. Again the magnitude and clinical importance remains to be
clarified (Farkas and Greenblatt, 2008). A recent review collates the
numerous fruit juices and herbal supplements which can lead to clinical
changes in the oral bioavailability of drugs (Stieger et al., 2017).
Another potential mechanism of food effect exists for drugs which
are subject to high first pass extraction because in such cases, bioa-
vailability is sensitive to the changes in hepatic and splanchnic blood
flow which occur after ingestion of food. Food intake was reported to
increase bioavailability of propranolol (McLean et al., 1981) and
pharmacokinetic modelling indicated that this could be due to de-
creased first-pass liver extraction (McLean et al., 1978). More recently,
physiologically based pharmacokinetic models for propranolol and
ibrutinib, another drug with high hepatic extraction, were applied and
a positive food effect was simulated (Rose et al., 2017). In the case
when first pass metabolism is saturable, it is possible that an increase in
hepatic blood flow with food reduces the concentrations of drug during
first pass and desaturation of metabolism. This would then result in an
increase in first-pass extraction and thus, a negative food effect. Such a
case was reported for tacrine which showed a significant decrease in
systemic exposure when taken with food (Welty et al., 1994).
Food can also cause changes in urinary pH by processes like alka-
linisation due to milk intake or due to a pure vegetarian diet or con-
versely acidification caused by a very protein rich diet. Since mainly the
non-ionised form of acids or bases are reabsorbed after glomerular fil-
tration or secretion, changes in urine pH can lead to a change in
pharmacokinetics of drugs eliminated by the kidneys. Thus it has been
recommended that diet should be kept stable during treatment with
memantine as its pharmacokinetic profile is considerably affected by
urine pH (Freudenthaler et al., 1998).
7. Specific food-drug interactions
Most often, the chemical composition of oral drug products is re-
latively simple as they are based on a single drug or a mixture of only a
few drugs. However, the presence of various excipients can lead to more
complex chemical composition. Usually, excipient selection is based on
their chemical and pharmacological inactivity and, absence of phar-
macokinetic and pharmacodynamics interactions with the drug(s). In
certain cases, the addition of excipients preserves the drug from phar-
macokinetic problems such as pH degradation, or improves patient
compliance (e.g. colourants, taste masking agents). Analogous to drug
products, food is also a mixture of different chemical entities endowed
with a determinable structure and specific (re)active moieties.
Nonetheless, it is clear that food is a very complex chemical system, in
which low and high molecular weight components are mixed together
and all of them can, in principle, cause specific food-drug interactions
that can be classified in terms of binding properties. Adducts could be
typically generated by covalent bonds between drugs and food com-
ponents such as proteins (Liebler, 2008). Conversely, non-covalent
complexes, can occur when weak interactions such as salt bridges,
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hydrogen bond or hydrophobic contacts (Neel et al., 2017) are estab-
lished between them. In order to have an effect on oral drug absorption,
these interactions must generate adducts or complexes with chemical
physical properties significantly different from the original reactants. In
particular, parameters such as molecular weight and logP are relevant
to control the absorption via biological membranes by means of passive
diffusion (Duffy and Jorgensen, 2000). In recent years, in silico methods
have been further optimised to also predict ADME properties (Hou and
Wang, 2008).
Some well-known examples of specific food-drug interaction are
detectable especially in the field of chelating compounds, i.e. those able
to form stable complexes preferably with bivalent cations such as cal-
cium or magnesium widely present in many foods, stable complexes.
The chemical structure of these chelating drugs can easily explain the
reasons of the complexing properties because they expose heteroatoms
such as oxygen and nitrogen in the correct conformation for the metal
coordination. Tetracyclines (Ziółkowski et al., 2016) and quinolones
(Stojkovic et al., 2014; Uivarosi, 2013) have been demonstrated to
create complexes with cations of foods or antacids (Ogawa and Echizen,
2011) with absorption characteristics dramatically different from the
free drug. An exhaustive specific food-drug interaction analysis for
other kind of non-metal coordination is not available in literature.
However, the advent of novel in silico and in vitro approaches will
hopefully speed up the progress of knowledge and provide new insights
into this topic.
In the following chapter, various specific food-drug interactions
occurring primarily on a pharmacokinetic level will be discussed. Apart
from well-known and highly relevant examples such as grapefruit juice,
milk and ethanol, we will also address specific effects of functional
foods on oral drug delivery.
7.1. Grapefruit juice
In the following section, an overview will be provided related to the
specific interactions between grapefruit juice and metabolising en-
zymes. In a second part, the interactions between grapefruit juice and
uptake/efflux transporters will be discussed. The clinical relevance of
these interactions will be demonstrated by literature examples for drug
compounds that are depending on these enzymes/transporters for me-
tabolism or absorption, respectively.
7.1.1. Interactions with metabolising enzymes
Inhibition of intestinal first-pass metabolism may increase the
absorption of drug substrates of the corresponding enzymes. A well-
known example is an inhibition of the intestinal cytochrome P450
(CYP) 3A enzymes by grapefruit juice (Citrus paradisi Macfad) (Ameer
and Weintraub, 1997; Dresser et al., 2000; Murray, 2006). Fur-
anocoumarins (such as bergamottin and 6′,7′-dihydroxy-bergamottin)
have been identified as the potential constituents in grapefruit in-
hibiting these intestinal CYP3A enzymes, resulting in an increase in
systemic exposure for defined substrates (Dresser et al., 2000). A sig-
nificant effect of grapefruit juice on the absorption of CYP3A4 meta-
bolised drugs has been demonstrated in humans (Fleisher et al., 1999;
Glaeser et al., 2007; Wagner et al., 2001). This interaction was dis-
covered by chance in an interaction study between felodipine (dihy-
dropyridine, Ca2+ antagonist) and ethanol. Grapefruit juice was used to
mask the taste of ethanol. Felodipine undergoes high presystemic (first-
pass) CYP3A4-mediated metabolism in the gut and liver resulting in a
low bioavailability (15%). Subsequent studies showed that grapefruit
juice reduced pre-systemic felodipine metabolism via an interaction
with CYP3A4 present in the intestinal wall. The effect of grapefruit juice
can, therefore, lead to an increase in felodipine in the systemic circu-
lation (systemic AUC and Cmax) and this effect can last longer than 24 h.
An amount of 250mL of grapefruit juice increases the AUC and Cmax to
267% and 345%, respectively (Fig. 10) (Lown et al., 1997). The com-
bination of grapefruit juice and felodipine resulted in lower blood
pressure and more often orthostatic hypotension.
The magnitude of the effect of food on the activity of metabolising
enzymes and intestinal transporters varies greatly from person to
person, depending on the intrinsic differences in the activity of meta-
bolising enzymes and transporters in the intestine so that individuals
with, for example, higher CYP3A4 levels also have a higher propor-
tional increase. The decreased expression of CYP3A4 with concomitant
intake of grapefruit juice indicates that it is not just a competitive in-
teraction. Since the mRNA for CYP3A4 is unchanged, the interaction
between diet and CYP3A4 is likely to be in the post-translational me-
chanism, e.g., by accelerated CYP3A4 degradation by means of down-
regulation. In order to recover the enzymatic activity, a completely new
de novo synthesis is needed, which explains the long effect of grapefruit
juice (Bailey et al., 1998; Glaeser et al., 2007).
7.1.2. Interactions with uptake/efflux transporters
Recently, it has been discovered that the P-gp can limit the bioa-
vailability of many orally administered drugs by transporting the sub-
strate back into the intestinal lumen. In an in vitro study of flavonoid
components from grapefruit juice, it was discovered that the efflux of
the P-gp substrate vinblastine decreased. There was a concentration-
dependent nutritional interaction of grapefruit juice on the perme-
ability of vinblastine across the Caco-2 cells. Higher concentrations of
grapefruit juice resulted in a lower efflux permeability of vinblastine
(Wagner et al., 2001).
Besides P-gp, grapefruit juice also inhibits uptake transport by the
organic anion transporter peptide 1A2 (OATP1A2). In a study by
Glaeser et al., it was shown that the administration of grapefruit juice
can lower the plasma levels of fexofenadine in humans without fex-
ofenadine undergoing significant metabolism. Based on in vitro studies,
it was shown that grapefruit juice can inhibit the transporter OATP1A2.
The proof-of-concept was clearly demonstrated when fexofenadine was
used in a human PK study to evaluate the function OATP1A2. The
plasma concentration of fexofenadine was measured in healthy volun-
teers who were administered 300mL of grapefruit juice at 0, 2 or 4 h
prior to the intake of fexofenadine. Concomitant administration of
grapefruit juice and fexofenadine resulted in an AUC0–8 h that had
dropped by 52% compared to the test condition when fexofenadine was
co-administered with water. Drinking grapefruit juice 2 h before taking
fexofenadine reduced the average AUC by 38% and drinking grapefruit
juice 4 h in advance had no effect on drug absorption (Bailey et al.,
1998; Glaeser et al., 2007).
Fig. 10. Effect of grapefruit juice on mean felodipine plasma concentrations.
Felodipine plasma concentrations were measured after the oral administration
of 10mg felodipine with either water, after the first glass of grapefruit juice
(8 oz.), or after 5 d of thrice daily administration of grapefruit juice.
Adapted from Lown et al., 1997.
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7.2. Milk
Whole fat cow's milk contains has a total caloric content of 65 kcal/
100mL and contains 3.7 g of fat, 4.6 g of carbohydrates, and 3.4 g of
protein per 100 g, which contribute to approximately 50%, 30% and
20% of the total caloric content, respectively (Jensen, 1995). In com-
parison to the meal proposed by EMA and FDA (EMA, 2012; FDA,
2002), milk is a homogenous liquid with up to 20% more calcium
(Walstra et al., 2006). Based on the similarities between milk compo-
sition and the reference meal (Guimarães et al., 2018), milk-based
biorelevant media to simulate composition of gastric contents in the fed
state have been proposed (Diakidou et al., 2009). Intragastric drug
solubility has been estimated in milk-based biorelevant media digested
with pepsin and lipase to simulate the digestion and lipolysis in the fed
state. Solubility measurements in these media resulted in solubility
values that were similar to the solubility values estimated ex vivo in
gastric contents aspirated from healthy adults in the fed state (Diakidou
et al., 2009).
Positive food effects on the absorption of the lipophilic drug lume-
fantrine have been observed when the drug was administered with milk
and a fat-enriched meal, due to solubilisation effects (Mwebaza et al.,
2013). However, food effects were not captured when milk was used
instead of the meal proposed by the regulatory agencies. Data with milk
could deviate from data with the meal due to milk-specific drug inter-
actions, such as chelate formation and drug protein binding (Singh,
1999).
Multivalent ions present in milk (e.g. Ca2+, Mg2+) can chelate with
drugs belonging to several classes (e.g. bisphosphonates, tetracyclines)
and the resulting complexes are not available for absorption.
Tetracyclines should be taken without milk or dairy products to avoid
decrease in exposure due to formation of insoluble chelates of tetra-
cyclines in the presence of calcium (Singh, 1999). Recent studies in
healthy humans showed that even a relatively small volume of milk
which contains an extremely low amount of calcium can severely im-
pair the absorption of this drug (Jung et al., 1997). The oral bioavail-
ability of demeclocycline decreased by 83% when taken with milk,
while drug administration after a dairy-free meal resulted in a positive
food effect, as shown in Fig. 11 (Neuvonen, 1976).
When compared with the fasted state, drug exposure in humans for
minocycline and tetracycline was also lowered by 27% and 65%, re-
spectively, when co-administered with milk. The administration of
minocycline and tetracycline after dairy-free food, however, reduced
drug plasma levels to a lesser extent when compared with milk; the
AUC after milk compared to meal consumption decreased by 17% and
36%, respectively (Leyden, 1985). In contrast, doxycycline experienced
no food effects when administered with milk or diverse nutrient-specific
meals (Neuvonen, 1976; Welling et al., 1976). Based on data from
healthy adults, the exposure to ciprofloxacin, an antibiotic drug be-
longing to the class of fluoroquinolones, is reduced with milk by
30–36% when compared with its administration with water because of
chelate formation with calcium (Hoogkamer and Kleinbloesem, 1995;
Neuvonen et al., 1991). However, ciprofloxacin plasma levels remained
unchanged when the drug was administered with water or after a
standard meal without milk (Ledergerber et al., 1985; Neuvonen et al.,
1991), or when administered with a high-fat high‑calcium breakfast
(Frost et al., 1989). The lack of a negative food effect in the presence of
chelating ions in the high-fat high‑calcium breakfast was explained by
unavailability of free calcium ions for drug chelation due to possible
trapping of calcium in the mixed meal components (Frost et al., 1989).
Although most fluoroquinolones chelate with multivalent ions (Läer
et al., 1997), interactions between milk and fluoroquinolones are not
always observed; e.g. the enoxacin and ofloxacin extent of absorption in
humans was scarcely affected after administration with milk compared
to a milk-containing and milk-free standard breakfast (Dudley et al.,
1991; Lehto and Kivisto, 1995; Singh, 1999). The antiarrhythmic drug
sotalol chelates with multivalent ions (Läer et al., 1997) and exhibits a
negative food effect when administered with milk (AUC decreased by
27% and Cmax by 33%) and milk-containing meals (AUC decreased by
37% and Cmax by 40%); herein it should be noted that the drug levels
achieved for sotalol taken with milk were greater compared to a milk-
containing meal (Kahela et al., 1979). A critical milk-related food-drug
interaction was shown for estramustine due to a formation of a poorly
absorbable calcium-complex (Gunnarsson et al., 1990). Drug absorp-
tion was significantly decreased with milk compared to low-calcium
water and to a low-calcium breakfast with an AUC reduction of 63%
and 43%, respectively (Gunnarsson et al., 1990).
Another mechanism for milk-related drug interactions is the specific
protein content of milk when compared with the reference meal, with
casein being the major contributor to the total milk protein content by
approximately 85%. However, its relative content in the protein frac-
tion of the standard meal is considerably lower (18%). Drug binding to
proteins in milk is mainly dictated by drug binding to casein and a
linear correlation between drug binding to casein solutions and to milk
was found for several drugs (Stebler and Guentert, 1990). In vitro drug
binding studies performed using skimmed and full-fat milk associated
the bound to free drug concentration ratio to drug lipophilicity
(Macheras et al., 1990). In line with in vitro studies showing that up to
52% of phenytoin was bound to skimmed milk components, adminis-
tration of phenytoin in healthy adults resulted in a reduction of the AUC
by half when ingested with milk (Macheras et al., 1991). In accordance
to these findings, clinical investigations aiming at identifying the in-
fluence of carbohydrates, fats, or proteins in phenytoin exposure re-
vealed that drug absorption was reduced only after protein intake
(Johansson et al., 1983).
A rather unusual drug-milk interaction concerning the cytostatic
drug 6-mercaptopurine and its metabolism via the enzyme xanthine
oxidase might lead to reduced drug exposure (de Lemos et al., 2007).
Due to high concentrations of xanthine oxidase in milk, the co-admin-
istration might lead to an increased inactivation of the drug; thus, se-
paration of the timing of 6-mercaptopurine intake and milk was pro-
posed by the authors (de Lemos et al., 2007).
7.3. Ethanol
Ethanol (alcohol) is one of the most widely used legal drugs in the
world and therefore, specific interactions with certain drugs can occur.
However, it should always be considered that alcohol intake also leads
to several changes of human GI physiology and thus, unspecific inter-
actions with drug administration may also occur contribute to the ob-
served effect.
Fig. 11. Mean serum concentrations [μg/mL] after administration of 300mg
demeclocycline with water (○), after a dairy-free meal (■), and after admin-
istration with 240mL of milk (△).
Adapted from Neuvonen, 1976.
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7.3.1. Interactions with drugs
The consumption of alcohol can affect the processes of dissolution
and absorption, but can also have downstream effects on metabolism
and elimination.
When compared with intake with water, the solubility of lipophilic
compounds (BCS class II/IV) in luminal fluids can be higher in the
presence of ethanol (Amidon et al., 1995; Fagerberg et al., 2015), which
leads to a higher concentration gradient between luminal fluid and
plasma. As a result, higher plasma concentrations arise due an ac-
celerated and more effective intestinal uptake of the drug.
Different groups have studied the effect of alcohol on the apparent
solubility (Sapp) and the absorption of nine lipophilic compounds in
fasted state simulated gastric fluid (FaSSGF) in the presence of 0% and
20% ethanol (pH 2.5). These experiments showed that ethanol causes a
significant increase in solubility for non-ionised compounds (up to 14
times higher) and for several weak acids (up to 13 times higher). For the
non-ionised compounds such as felodipine or griseofulvin, intestinal
absorption was also increased. In case of felodipine, even a two-fold
higher intestinal uptake was observed (based on in silico compartmental
absorption simulations in GI-Sim). In contrast, the increased solubility
of the weak acids such as indomethacin or ibuprofen did not result in an
increased absorption. This effect was explained by the authors by the
high solubility of these compounds in the intestine where weak acids
are ionised. Consequently, the drugs were too polar to cross the bio-
logical membrane. The solubility of weak bases (dipyridamole, cin-
narizine) was not affected by the presence of ethanol since they are
completely ionised at the acidic pH of the stomach (Fagerberg et al.,
2015).
The same authors also studied the effect of ethanol on the apparent
solubility of 22 poorly soluble compounds in fasted state simulated
intestinal fluid (FaSSIF), to which they added 0%, 5% and 20% ethanol
(pH 6.5). The effect of 5% ethanol on the solubility was negligible for
most compounds. In contrast, for 13 of the 22 compounds, a three-fold
increase in solubility was observed in the presence of 20% ethanol. The
increase in solubility was greater for neutral and acidic compounds
compared to the basic compounds which exhibited a more compound-
specific influence. The authors indicated that an increase in solubility of
compounds in the small intestine is probably temporary because of the
Fig. 12. Alcohol concentration in the stomach and the small intestine after intake of 500mL of beer, 200mL of wine and 80mL of whisky. The different alcoholic
drinks were given under fasted (left) and fed (right) conditions.
Adapted from Rubbens et al., 2016.
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rapid dilution and absorption of ethanol in the small intestine
(Fagerberg et al., 2012). This suggestion is in line with the study by
Rubbens et al. who investigated intraluminal ethanol concentrations in
fasted and fed healthy volunteers after the consumption of alcohol
beverages (Fig. 12) (Rubbens et al., 2016). Following the consumption
of beer, wine or whisky, low and rapidly declining intestinal ethanol
concentrations were observed. Intraduodenal ethanol concentrations
did not reach levels high enough to affect local drug solubility as was
previously stated by Fagerberg et al. (Fagerberg et al., 2012).
Ethanol does not only increase the absorption of BCS class II drugs
but also those belonging to BCS class I (highly soluble, highly perme-
able) (Amidon et al., 1995). This was demonstrated by a study by Hayes
et al. in seven subjects where the mean plasma Cmax of diazepam almost
doubled after drinking 30mL of a solution consisting of 50% ethanol
and 50% distilled water (Hayes et al., 1977). Fagerberg et al. com-
mented that despite this drug belongs to BCS class I, diazepam does not
show a very high solubility in the intestinal media (compared to the
administered dose). Therefore, in the presence of alcohol, diazepam
may rapidly dissolve and will be quickly absorbed (Fagerberg et al.,
2015). This fact is not unimportant since diazepam is often combined
with alcohol. The National Institute on Drug Abuse reported 40 years
ago that alcohol was the most common cause of emergency admissions
by taking drugs. If the cause was the intake of alcohol with drugs,
diazepame was the most common drug (Hayes et al., 1977).
After systemic absorption, ethanol is metabolised by alcohol dehy-
drogenase (ADH) and the CYP2E1, an enzyme that is also responsible
for the biotransformation of xenobiotics and fatty acids. Therefore,
clinically significant pharmacokinetic interactions with ethanol can
also occur when drugs are administered that are substrates of these
enzymes. Fortunately, this includes only a limited number of drugs such
as paracetamol or theophylline.
7.3.2. Interactions with oral drug products
The drug release profile of certain drug products can be strongly
influenced by the co-administration of alcohol. A change in release of
the drug in the presence of alcohol can be caused by the drug itself (e.g.,
solubility changes of the drug or excipients) and/or by the environment
in which the drug is released (e.g., stimulation of acid secretion). The
extent to which alcohol has an impact on drug release depends on (i)
the duration of exposure and (ii) the volume and concentration of al-
cohol that is administered. The volume and concentration of the present
alcohol in the gastrointestinal (GI) tract is mainly determined by the
rate of drinking and the nature of the alcoholic beverage (Lennernäs,
2009).
In daily life, alcohol is often combined with drugs and especially
with analgesic drugs such as opioids (synergistic effect). Ethanol en-
sures that patients are less aware of the pain or reduce the stress as-
sociated with pain (Johnson et al., 2012). Since the worldwide con-
sumption of analgesics and following a recently reported and possibly
fatal interaction of ethanol with Palladone™ (Murray and Wooltorton,
2005), a lot of literature studies focus on the interactions between al-
cohol and drug products. The incident of Palladone™ has aroused the
interest of industry and academia to perform more research related to
alcohol and controlled-release (CR) formulations.
Dissolution tests are essential to investigate whether CR prepara-
tions are sensitive to ethanol or not. Simultaneous intake with ethanol
can influence the bioavailability of the CR formulation and, in a worst-
case scenario, alcohol can cause dose dumping (ADD). In vitro tests can
be useful to predict the effects of certain alcohol-drug product inter-
actions in vivo (EMA, 2019b). Human PK studies involving ethanol are
rarely performed because of the potential risk for dangerous side effects
in patients.
7.4. Functional food
Food is usually considered functional if it affects beneficially one or
more target functions in the body, beyond adequate nutritional effects,
in the way that is relevant to either an improved state of health and/or
reduction of risk of disease (“Scientific Concepts of Functional Foods in
Europe Consensus Document”, 1999). Functional foods must remain
foods and must demonstrate their effects when consumed as a part of
normal dietary pattern. A functional food can be; a natural whole food,
Table 2
Major classes of bioactive ingredients in functional foods.
(Abuajah et al., 2015; Hasler, 2002)
Bioactive ingredient Sources Health benefita
Probiotics (Lactobacillus, Bifidobacterium) Dairy products Modification of intestinal microflora,
Improvement of gastrointestinal health
Polyphenols (anthocyanidins, catechins, flavonoids, tannins) Fruits, vegetables, plant extracts, fortified foods Antioxidant effect,
Anticancer properties,
Reduced risk of cardiovascular diseases
Carotenoids (β-carotene, α-carotene, lycopene, lutein, astaxantine) Fruits, vegetables, plant extracts, fortified foods Antioxidant effect,
Anticancer effects
Dietary fibre (soluble, insoluble, fructo-oligosaccharides) Cereals, fruits, vegetables, mushrooms Anticancer effects,
Reduced risk of cardiovascular diseases,
Immunomodulatory effects,
Cholesterol-lowering effects,
Laxative effect,
Prebiotic effect
Plant sterols and stanols Cereals, fortified foods Cholesterol-lowering effect,
Soy isoflavones (daidzein, genistein) Soy-based foods Reduction of menopause symptoms,
Anticancer effects,
Reduced risk of cardiovascular diseases
(n-3) fatty acids (linolenic, eicosapentaenoic acid, docosahexaenoic acid) Fatty fish, fortified foods Reduced risk of cardiovascular diseases,
Reduced triglyceride levels,
Improved neurological functions
Conjugated linoleic acid Meat and dairy products Anticancer effect (breast cancer)
Glucosinolates and indols Cruciferous vegetables Anticancer effect
Organosulfur compounds Garlic Immunomodulatory effects,
Anticancer effect,
Cholesterol-lowering effect
a Listed health benefits refer to consummation of listed bioactive ingredients in their natural form as part of regular nutrition and are corroborated by large
epidemiological studies or interventional human trials.
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a processed food to which a bioactive (e.g. minerals and vitamins or
other biologically active compounds) has been added (fortified food)
and food where the level of naturally occurring bioactive has been
modified (Gul et al., 2016). Examples of the major categories of
bioactives that can be found in functional foods, their sources and po-
tential health benefits are summarised in Table 2.
Significant efforts are currently being made to reach consensus on
scientific concepts of functional foods by using science-based sup-
porting evidence on positive effects on physiological functions, for ex-
ample, by the FUFOSE concerted action in Europe (“Scientific concepts
of functional foods in Europe: Consensus document”, 1999). On the
other hand, additional actions are needed in order to adequately con-
sider certain safety aspects of functional foods. Major safety issues are
related to functional foods containing complex plant extracts and
bioactives not normally present in foods or present in significantly
lower concentrations. Safety considerations should take into account
their acute/chronic toxicity, allergenic potential as well as their po-
tential to increase the risk for food-drug interactions. This chapter will
specifically focus on potential functional food-drug interactions.
Thereby, we will focus on different classes of bioactive ingredients that
are either exclusively present in certain types of functional foods or are
present in functional foods in significantly higher amounts in compar-
ison to natural (basic) foods.
7.4.1. Polyphenolic compounds
Polyphenolic compounds are naturally present in a variety of foods,
however, their content and diversity are additionally increased in
functional foods enriched with plant extracts. They can be added to
conventional food to exert its potential health-promoting properties,
but can also be used as natural food additives (preservatives and
Table 3
Examples of possible drug interactions with polyphenols/plant extracts used as functional foods.
Plant extract Major active ingredient/s Effect/s Clinical evidence for interactions with Refs
Green tea (Camellia sinensis) Catechins (epigallocatechin-3-
gallate) etc.
Antiplatelet activity,
Inhibition of drug transporters (OATP1A1),
Inhibition of CYP1A1, CYP1A2, CYP2B6, CYP2C8,
CYP2C9, CYP2D6, CYP3A4, UGT1A1 and
UGT1A4
Caffeine
Tizanidine
Topical cocaine
Nasal cocaine
a,b
Grape seed (Vitis sp.) Resveratrol Inhibition of intestinal CYP3A4,
Inhibition of CYP2C9 and CYP2D6,
Weak induction of CYP1A2
Not reported c
Turmeric (Curcuma longa) Curcuminoids (e.g. curcumin) Anticoagulant effect,
Hypoglycaemic effect,
Antiestrogenic effect,
Inhibition of CYP1A1, CYP1A2 and CYP3A4,
Inhibition of drug transporters (p-gp)
Talinolol d,e,f
Soy (Glycine max) Isoflavons (genistein, daidzein) Binding to estrogen receptors,
Diuretic effect,
Hypoglycaemic effect,
Inhibition of CYP1A, CYP1B and CYP2 enzymes,
Biotransformation (activation) by gastrointestinal
microflora
Anti-aromatase agents
CYP3A4-inducing drugs: encorafenib, venetoclax,
guanfacine
g,h
Tyramine (in fermented soy
products)
Metabolization by monamine oxidase (MAO) MAO inhibitors: phenelzine, tranylcypromine
Milk thistle (Silybum
marianum)
Silymarin Glucose lowering effect in diabetes type 2
patients,
Inhibition of UGT,
Inhibition of CYP2C9 and CYP3A4
Not reported i,j,k,l
St. John's wort (Hypericum
perforatum)
Hypericin, hyperforin Induction of CYP3A4,
Induction of CYP1A2, CYP2C9, CYP3A4,
Serotonin agonist
Various CYP3A4 substrates, e.g. digoxin,
nifedipine, talinolol, verapamil, indinavir,
ciclosporine, tacrolimus, Amytriptilin
CYP2C9 substrates: omeprazole
j,m,n,o
Rosemary (Rosmarinus
officinalis)
Caffeic acid derivatives,
rosmarinic acid etc.
INHIBITION of platelet aggregation,
Induction of CYP1A1 and CYP1A2
Not reported p,q
Thyme (Thymus vulgaris) Thymol, carvacrol, apigenin,
luteolin, caffeic acid etc.
Inhibition of acetylcholinesterase,
Anticoagulant effect
Not reported r,s
a Albassam and Markowitz, 2017.
b Momo et al., 2004.
c Detampel et al., 2012.
d Adiwidjaja et al., 2017.
e Bahramsoltani et al., 2017.
f Lee et al., 2018.
g Ronis, 2016.
h Shulman et al., 1989.
i Di Pierro et al., 2012.
j Markowitz, 2003.
k Sridar et al., 2004.
l Woodbury and Sniecinski, 2016.
m Henderson et al., 2002.
n Murphy et al., 2005.
o Mouly et al., 2017.
p Debersac et al., 2001.
q Naemura et al., 2008.
r Jukic et al., 2007.
s Tognolini et al., 2006.
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antioxidants). As aforementioned, the complexity of their chemical
composition and concentration levels above those normally present in
food, increase the possibility of the occurrence of clinically significant
functional-food drug interactions. Due to antidiabetic, anticoagulant,
hypotensive and other health-promoting properties of polyphenols used
as functional food ingredients, pharmacodynamic-type interactions are
possible with respective drug classes. However, most of the known in-
teractions involve drug metabolising enzymes (phase I and phase II)
and transport proteins. Polyphenols undergo extensive biotransforma-
tion and show high affinity for efflux transporters in the gut; therefore,
their bioavailability is limited but the potential for pharmacokinetic
interactions with drugs at gut level is high (Lambert et al., 2007).
Among phase I enzymes, CYP3A4 is known to be the main enzyme
involved in intestinal and hepatic metabolism of drugs and data on
food-drug interactions involving CYP3A4 are accumulating. In majority
of cases, dietary polyphenols inhibit CYP3A4 activity and increase the
actual dose of the drug, although quercetin, genistein and certain fla-
vons produce opposite effects by activating the enzyme (Basheer and
Kerem, 2015). Soy isoflavons and methoxylated flavonoids (apigenin)
are extensively metabolised by CYP1A and 1B isoforms, accounting
partially for their anticancer activity but also increasing their drug in-
teraction potential (Lambert et al., 2007). Green tea catechins inhibit
the activity of numerous CYP enzymes, but also undergo extensive
methylation, glucuronidation and sulfation affecting the activity of
phase II enzymes (Albassam and Markowitz, 2017). Significant inter-
actions also occur at the level of transport proteins (ABC) that play a
key role in determining drug absorption, elimination as well as drug
entry into some pharmacologically important compartments. These
transporters interact significantly with dietary flavonoids and in such
way affect the bioavailability of anti-cancer agents, cardiac drugs, HIV
protease inhibitors, immunosuppressants, steroids and many other
drugs (Montanari and Ecker, 2015; Morris and Zhang, 2006). Table 3
lists some examples of polyphenols/plant extracts commonly used in
functional food production and their possible interactions with drugs.
7.4.2. Organosulfur compounds
Organosulfur compounds (OSC) are functional compounds mainly
present in two groups of vegetables: garlic and onion (that contain S-alk
(en)yl-L-cysteine sulfoxides) and cabbage, cauliflower and kale (that
contain S-methyl L-cysteine sulfoxide) (Munday, 2012). Epidemiolo-
gical studies indicate positive associations of their consumption with
decreased risk of cancer and other diseases (Nicastro et al., 2015). Due
to antiplatelet, glucose lowering and antihypertensive properties, garlic
and onion might enhance (adverse) effects of anticoagulants, anti-
diabetics and antihypertensive drugs (Eldin et al., 2010; Hou et al.,
2015; Hubbard et al., 2006; Woodbury and Sniecinski, 2016; Xiong
et al., 2015). Garlic (extracts) inhibits CYP2E1 and induces CYP3A4 and
should be used cautiously in patients taking drugs metabolised by these
enzymes (paracetamol, chlorzoxazone, and anaesthetics; calcium
channel blockers, chemotherapeutic agents, antifungals, glucocorti-
coids and others) (Gurley et al., 2002; Ho et al., 2010). Evidence from in
vivo research suggests that broccoli consumption induces CYP1A2 and
CYP2A6 enzymes so theoretically, broccoli might increase the meta-
bolism and reduce the levels of certain drugs (Hakooz and Hamdan,
2007).
7.4.3. Non-starchy and sulphated polysaccharides
Non-starchy and sulphated polysaccharides such as fucoidan are
present in medicinal mushrooms and some seaweeds. Due to their
health-promoting properties, they are increasingly used as novel func-
tional food ingredients, mainly in the form of medicinal mushroom
extracts. Given that clinical research shows that taking maitake mush-
room polysaccharide can theoretically lower blood glucose, combining
maitake mushroom with antidiabetic drugs might increase the risk of
hypoglycaemia (Konno et al., 2001). In one case report, maitake
mushroom increased the anticoagulant effects of warfarin probably due
to polysaccharide constituent of maitake mushroom that caused war-
farin dissociation from protein (Hanselin et al., 2010). Since in vitro
evidence suggests that shiitake mushroom extracts might stimulate
immune function, theoretically, taking shiitake mushroom might de-
crease the effects of immunosuppressive therapy (Dai et al., 2015).
7.4.4. Probiotics
Probiotics are major functional components of yogurt, although
nowadays are also present in other types of foods. As mentioned in
Section 7.2 dairy products (including yogurt) should not be admini-
strated with certain antibiotics such as ciprofloxacine or tetracycline
since they significantly reduce drug absorption (McEvoy, 1998;
Neuvonen et al., 1991). This effect is related to divalent cations but not
to probiotics. However, certain bacterial strains in yogurt can cause
infections in patients taking medications that suppress the immune
system (Kalima et al., 1996; Rautio et al., 1999), while concomitant
administration of certain antibiotics or antifungals might decrease the
effectiveness of probiotics (Lewis and Freedman, 1998; Xiao et al.,
2010). However, the potential of probiotics to alter the bioavailability
of drugs might be far more significant as obvious from the increasing
amount of scientific data stating that drug metabolism by the gut may
cause significant alterations in drug-induced pharmacodynamics and
toxicities (Noh et al., 2017; Wilson and Nicholson, 2017). Therefore,
probiotic-induced changes of the host microbiome must be considered
as the potentially important source of clinically significant interactions
and should be more closely studied in the future (see Section 3.5).
8. Contribution of the formulation to food-drug interactions
Food intake induces dynamic changes in the composition and vo-
lumes of luminal fluids as well as the patterns of GI motility which
ultimately affect the behaviour of orally administered drug products.
The main changes induced by food consumption are comprehensively
described in the earlier sections of this review, however, the main
strategies to overcome food effects by formulation will be discussed
herein. The consequences of food effects can be complex and proble-
matic, therefore, an orally administered drug product should ideally
have the same bioavailability irrespective of the fed or fasted state.
Where food effects are identified, there are generally three approaches
that drug development or regulatory scientists can implement to miti-
gate against a food effect including: 1) to consider an alternative lead
drug molecule that will not display food effect, however, this method is
complicated, expensive and can delay the drug development process; 2)
to apply specific instruction for how a drug is taken with regards to
food, although this is restrictive and may interfere with the patient's
daily life or to; 3) design a formulation which overcomes the overall
food effect. When compared with the other available strategies, the
latter is considered to be the most practical solution to circumvent
potential food effects (O'Shea et al., 2018; Varum et al., 2013).
Food-drug interactions can lead to a positive food effect whereby
food consumption increases drug bioavailability such as for poorly so-
luble drugs that are presented as immediate release formulations. In
addition, food can delay the disintegration of immediate release pro-
ducts in the stomach including tablets (Kelly et al., 2003), two-piece
capsules (Jones et al., 2012; Tuleu et al., 2007) and one-piece capsules
(Wilson and Washington, 1988). The principal cause of positive food
effects is the increase in dissolution and solubilisation of poorly water-
soluble drugs in the fed state. The release of bile salts and the presence
of exogenous solubilising species such as ingested lipids and their di-
gestion products, serve to enhance solubilising capacity of gastro-
intestinal fluid (O'Shea et al., 2018; Varum et al., 2013).
In order to mitigate positive effects, formulation strategies can be
implemented to boost drug bioavailability in the fasted state in order to
match that of the fed state, thereby eradicating a food effect. Such
approaches include amorphous and solid dispersions, lipid-based for-
mulations and nano-sized preparations (O'Shea et al., 2018).
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In other cases, food-drug interactions can contribute to a negative
food effect which decrease drug bioavailability. The most common
causes of reduced bioavailability in the fed state are the direct physi-
cochemical interactions between drugs (or drug products) and food.
One potential cause of this effect is the reduced diffusivity of drug in the
viscous postprandial upper GI tract. The increased viscosity can result
in either inhibition of disintegration of a formulation which prevent
drug release or hinder the diffusion of drug to the absorptive mem-
branes of the GI tract. This can be problematic for poorly permeable
drugs, particularly those with narrow absorption windows as by the
time viscosity has reduced in the distal gut, the absorption window has
been transited and absorption will be reduced. A second direct me-
chanism by which food can hinder drug absorption is by binding of
drug with food components (O'Shea et al., 2018).
To overcome negative food effects, the drug product can be for-
mulated to release further down the GI tract to minimise the interaction
of the drug with the ingested meal. Such an approach includes the use
of modified release formulations, particularly delayed release (e.g. en-
teric coated) systems. These formulations, however, may also be subject
to food effects in relation to delayed gastric emptying and have the
potential for dose dumping.
Food-mediated interactions of a modified-release formulation are
significantly reduced for multiparticulate systems (Varum et al., 2010).
Moreover, the small size and divided nature of multiparticulate for-
mulations reduce the risk of dose dumping. For example, enteric coated
erythromycin pellets resulted in lower variability and higher bioavail-
ability when compared with enteric coated tablets following food in-
take (Graffner et al., 1986). A similar outcome was achieved for the oral
bioavailability of acetylsalicylic acid when administered as enteric
coated granules which was shown to be less variable and unaffected by
the presence of food in contrast to enteric coated tablets (Bogentoft
et al., 1978). In general, the greater the size of the formulation, the
more prolonged the period of gastric emptying in the fed state and also
the greater the variability (Davis et al., 1986).
Adding further to the complication of the presence of food, the
timing of the meal further influences the transit of oral modified release
formulations. For example, a study which investigated the administra-
tion of a multiple-unit formulation 30min before food consumption
showed faster gastric emptying when compared with the fasted state
(Digenis et al., 1990). This suggest that food consumption contributes
to increase gastric motility and subsequently, gastric emptying. Small
intestinal transit is also accelerated following food intake which can
further affect oral bioavailability; for instance, erythromycin, which is
optimally absorbed in the small intestine, was lower in the fed state in
comparison to the fasted (Edelbroek et al., 1993). This was further
confirmed by a gamma scintigraphy study which investigated the
transit of formulations in the small intestine in three different feeding
conditions; 1) under the fasted state (tablet administered on an empty
stomach), 2) fed state (tablet administered after food) and 3) pre-feed
(tablet administered 45min before food). Under the pre-feed regimen,
small intestinal transit time was significantly shorter (100min) when
compared with the fasted (204min) or fed conditions (210min) (Fadda
et al., 2009).
As aforementioned, delayed release systems can be used to mitigate
a negative food effect. For instance, it has been shown that targeting
trientine to the middle or lower part of the small intestine by means of
an enteric coating abolished the negative food effects observed when
given as an oral solution in the fed state (Tanno et al., 2008). This has
been attributed to the delayed gastric emptying of the enteric coated
formulation and the distal release of the drug, thus, avoiding physico-
chemical food-drug interactions. Similarly, when administered as a
capsule, the bioavailability of DX-9065 was reduced in the fed state.
Designed as a modified release enteric coated tablet, however, oral drug
bioavailability was successfully increased 5-fold by limiting interactions
with bile salts, negating negative food effects (Fujii et al., 2011). More
recently, an enteric coated risedronate product has been reported which
offers the possibility of being safely administered with food. Currently
registered drug products with risedronate are required to be taken on
an empty stomach to prevent the drug from chelating with food com-
ponents. The reformulated tablet containing the drug and ethylene-
diaminetetraacetic acid (EDTA) was coated with a layer of an enteric
polymer which released its contents in the small intestine, thereby
circumventing the segments of the GI tract where food-drug interac-
tions significantly occur. At this level, EDTA can act as a scavenger for
food components such as calcium ions which consequently allow the
drug to be freely absorbed (Pazianas et al., 2013).
9. Real-life dosing conditions – regulatory considerations
The extent of food-drug interactions may depend on the way in
which a drug substance is manufactured into the drug product. Thus,
user instructions (warnings or recommendations) in the product in-
formation (in Europe: SmPC/PL) can either be drug substance-specific
or product-specific. The rationale for the warnings on food-drug inter-
actions in user instructions in the product information can also be quite
diverse and may vary from rather strict to soft (Medicines Bank,
Netherlands, 2019; Paśko et al., 2017). For example, a well-known and
strict warning is that the product should not be used with certain types
of food, e.g. for the iron supplement ferrous fumarate it is stated that
milk, tea or coffee should not be taken within 2–3 h after intake as this
reduces absorption. A less strict warning is included for the calcium
antagonist nifedipine, where it is stated that the use of grapefruit juice
is discouraged as concurrent use of nifedipine and grapefruit juice re-
sults in an increased plasma concentration and prolonged effect. For
levothyroxine, a softer warning is included by stating that the absorp-
tion from the intestine may decrease by soy and fibre containing food,
and that dose adjustments may be needed, especially when starting or
discontinuing soy containing products (Medicines Bank, Netherlands,
2019). In all cases, the strictness of the advice in the SmPC is dependent
on the PK/PD relationship and the clinical consequences with respect to
efficacy and safety. It should also be acknowledged that warnings may
fail to be included in the user instruction because of lack of data or just
because the SmPC/PL is outdated (San Miguel et al., 2005).
The user instruction may also indicate that the product should on
purpose be taken with food or drink, which actually implies an in-
struction. This is commonly done to intentionally alter absorption or to
mitigate side effects. For example, non-steroidal anti-inflammatory
drugs such as diclofenac or the antibiotic amoxicillin/clavulanic acid
should be taken prior or during a meal to reduce the risk for gastric
complaints. Acamprosate, a drug used in alcohol treatment therapies, is
another drug that should be taken with food (Medicines Bank,
Netherlands, 2019). Increasingly, the intake of drugs with antioxidants
that are naturally occurring in food is investigated to protect the side
effects of mutagenic drugs like cisplatin or methotrexate (Famurewa
et al., 2017; Said Salem et al., 2017).
In real world settings, many patients and health-care professionals
consider that the lack of a warning or an advice on the joint intake of a
drug product with food or drink implies that there is none. They
commonly use this understanding to consider that it is no problem to
co-administer a drug product with (semi-solid) food or drink on a spoon
or to mix the product through the whole meal or a full glass of any drink
other than water. Likewise, it is often not considered a problem to
modify the product first, e.g. crushing tablets or opening capsules. All
these methods of administration are commonly adopted to ease or to
ensure safe swallowing, e.g. in young children, patients who are se-
verely ill, or in patients who are facing cognitive problems like de-
mentia for example. In children, these methods are also commonly used
to improve taste, however this reason is less important in (older) adults
(Haw and Stubbs, 2010; Stegemann et al., 2012). When product mod-
ifications and/or co-administration or mixing with food or drink is no
longer possible to ensure easy and safe swallowing, or for ease of work,
drug products may also be administered through a feeding tube
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(Demirkan et al., 2017). In rare situations, food or drink may also be
used to cover the intake of the drugs (Haw and Stubbs, 2010; Kala,
2012).
Patients and health care professionals do not often take into account
that mixing should only be used when co-administration is unavoid-
able, as it runs the risk that the patient will not swallow the whole meal
or drink the full glass and thus, not take the full dose. Patients also run a
greater risk of developing a resent to the food when the taste of the
whole meal is affected rather than one spoonful of food or drink (van
Riet-Nales et al., 2015). More importantly, from a regulatory perspec-
tive, the lack of an instruction means that the product should be taken
on its own or just with some water. This is because the co-administra-
tion or mixing implies a direct contact between the drug product and
the food, which may either have an effect on the drug substance itself
(e.g. stability or changes in particle size) or the specific characteristics
of the formulation (e.g. coating, liposomes etc.). For this reason, co-
administration is to be preferred over mixing, as the contact time and
area significantly increases in case of mixing. The risk of tube blockage
should also be considered in cases where food is used to administer a
drug product through an enteral feeding tube (EMA, 2019a; Demirkan
et al., 2017).
Companies may accept that in real world settings the co-adminis-
tration of a drug product with food or drink is sometimes unavoidable.
As such, pharmaceutical companies should aim to consider the devel-
opment of new drug products with the co-administration of food in
mind, specifically for use in children or the geriatric population (EMA,
2013, 2017). Thus, companies may voluntarily decide to provide a user
instruction for an alternative administration approach involving the
joint intake of their product with (semi-solid) food or drink. Such in-
structions on co-administering and mixing of the drug product with
food or drink should be clearly differentiated from the standard in-
struction to take the product on its own or with some water during a
meal. For example, the standard instruction for CREON 25.000 capsules
indicate that it can be taken during or immediately after any meal.
However, the capsules may also be opened to ease swallowing. The
capsule content (i.e. coated granules) should be then mixed with acidic
food (pH≤5.5) such as apple sauce, yogurt or fruit juice to not affect
the enteric coating. The same instruction applies for many other gastro-
resistant formulations if co-administered or mixed with food or drink as
there is a need to ensure gastro-resistance (Medicines Bank,
Netherlands, 2019).
10. Conclusion
This review has revealed that the co-administration of food or drink
can affect drug release (volume and composition of luminal fluids,
transit times, motility), absorption (uptake and efflux transporters),
distribution (lymphatic drug transport, lipoprotein and plasma protein
binding), metabolism and elimination (drug-metabolising enzymes and
drug transporters). Moreover, animal studies have suggested that the
microbiome can be another integral factor for oral drug bioavailability
and pharmacokinetics. With regards to specific food-drug interactions,
the effects of grapefruit on drug metabolising enzymes and uptake and
efflux membrane transporters; of milk on drug absorption and; of
ethanol on drug absorption, distribution, metabolism and elimination
are just the tip of the iceberg. Moreover, the administration of func-
tional foods and food supplements can also impact drug activity and
thus, there is a need of science-based supporting evidence not only on
positive effects and safety, but also on potential food-drug interactions.
However, many mechanistic studies are still based on in vitro and an-
imal models and in vivo studies in humans which confirm whether these
food-induced changes are relevant for drug activity are often lacking.
To advance the pharmaceutical arena, a better knowledge of the food-
induced changes affecting drug activity is required to understand
whether the design of a formulation which overcomes the overall food
effect could represent a successful strategy for future drug development.
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